PORPP NEW copy
Transcript of PORPP NEW copy
1
PORPP
D E P A R T M E N T O F P H A R M A C Y
U N I V E R S I T Y O F WA S H I N G T O N
‒P
harm
aceu
tica
l Ou
tcom
es R
esea
rch
and
Polic
y P
rogr
am
B I E N N I A L R E P O R T
2
C o n te n t sF R O M T H E D I R E C T O R 3
F R O M T H E D E A N 4
F R O M T H E D E PA R T M E N T C H A I R 4
P E O P L E & P R O G R A M S 5
O U R P R O G R A M & O U R M I S S I O N 6
A C A D E M I C P R O G R A M S 7
F A C U LT Y & S TA F F P R O F I L E S 8
F A C U LT Y F O C U S : T H O M A S H A Z L E T 11
O U R S T U D E N T S & F E L L OW S 12
H O N O R S & A WA R D S 14
R E S E A R C H P R O G R A M S & G R A N T S 16
A C A D E M I C & C O M M U N I T Y I N T E R FAC E 18
F A C U LT Y A C T I V I T I E S & S E R V I C E 19
C O R P O R AT E A D V I S O RY B OA R D 21
C O N F E R E N C E S & S Y M P O S I A 22
F A C U LT Y F O C U S : S E A N S U L L I VA N 23
G R A N D R O U N D S S E M I N A R S E R I E S 24
O U R P R E S E N T ; O U R F U T U R E 25
N E W F A C U LT Y 26
F A C U LT Y F O C U S : D AV I D V E E N S T R A 27
N E W A LU M N I 28
V I S I T I N G S C H O L A R S 30
G R A D UAT E P R O G R A M R E V I E W 30
G R A D UAT E E M P L OY M E N T 31
S E L E C T E D P U B L I C AT I O N S 32
G R A N T S , G I F T S , & A F F I L I AT I O N S 35
3
I AM PLEASED TO PROVIDE YOU with the biennial report of
the University of Washington Pharmaceutical Outcomes Research and
Policy Program (PORPP). This report catalogues the activities,
scholarship, and professional accomplishments of our faculty and
graduate students during 2000–2002. As you will see while you turn
the pages, these dedicated and hard working individuals have made
substantial achievements in their respective disciplines, too numerous
to list in this brief introduction. PORPP is extremely fortunate to have
scientists and students of the highest caliber.
Three organizational activities are worth noting. In the summer of
2001, Dr. Beth Devine joined us to serve as Associate Director. With
the expansion of graduate and educational activities, PORPP will
benefit from the additional support Dr. Devine can provide.
The PORPP graduate program underwent external review from peer
academic colleagues in 2001 at the request of the Dean of the Graduate
School. This is a standard procedure for University of Washington
departments and programs that offer graduate degrees. We received
very high marks for the PhD program and were granted a 10-year
accreditation by the Graduate School. Furthermore, we were asked to
consider expanding enrollment in the graduate program.
Also in 2001, we invited eleven colleagues, representing the pharma-
ceutical and managed care industry, to convene an external advisory
board. The board, chaired by Dr. Edward Bortnichak of Sanofi-
Synthelabo, met in November with the specific objective of giving
input on the content, direction, and quality of our graduate and
research programs as they relate to industrial needs. The outcome was
a focused list of recommendations to further enhance our program
offerings. We have begun to take up some of these recommendations
internally.
Finally, I would like to acknowledge the dedicated support from our
staff program coordinators, Penny Evans and Cindy Bush, who have
played a major role in the accomplishments that you see highlighted
throughout these pages.
—Sean Sullivan, Director
From the Director
4
AS YOU READ THIS BIENNIAL REPORT of the Pharmaceutical
Outcomes Research and Policy Program (PORPP), I am sure that you will
agree that in its few short years of existence PORPP has been one of the
outstanding success stories in our School of Pharmacy. From its inception in
1995 by Dr. Andy Stergachis, through its maturation under the masterful
guidance of its director, Dr. Sean Sullivan, PORPP has met its primary goal of
advancing the health of the public through improving decision-making
regarding pharmaceutical therapy and policy. Attesting to this achievement
are the many awards and honors bestowed on PORPP faculty and students for
their work, and the large number of news stories that have highlighted the
work. Furthermore, our advisory boards are insistent that we need to grow the
program to meet the demands of a society that wants improved health care at
a reasonable cost. As Irving Berlin once said, “The toughest thing about
success is that you’ve got to keep on being a success.” I am convinced that
PORPP will do just that, and am genuinely excited about its future.
—Sid Nelson, Dean, School of Pharmacy
From the Dean“Nothing succeeds like success.” Alexandre Dumas
From the Department ChairIT IS WITH GREAT PLEASURE that I offer my remarks to the 2000-2002
Biennial Report for PORPP. This report shows the continual growth and
success of the Program in many respects. During this period, the faculty has
expanded with the addition of several research, adjunct, and affiliate appoint-
ments (Drs. Devine, Patrick and Smith). The graduate program celebrated the
graduation of the first two classes of PhD students, and the first from the
combined PharmD-MS program. PORPP continues to expand the scope of its
research, education, and service activities. The tremendous success and
impact of the recent conferences and workshops sponsored by PORPP are
impressive. The research accomplishments of the faculty and their graduate
students have been repeatedly recognized by a number of national and
international scientific societies and professional organizations. The success
of PORPP is truly a distinction for the Department of Pharmacy and the
School as a whole. I congratulate the PORPP faculty for their accomplish-
ments, particularly in view of the relatively short history of the Program and
serious constraint in resources that this University has faced in the past.
I also want to take this opportunity to express my sincere appreciation to the
many colleagues in the academic and research communities, professional
organizations, and healthcare and drug industries for their continual support,
both in financial terms and collaborative opportunities.
—Danny Shen, Chair, Department of Pharmacy
55
PORPP
5
O U R P R O G R A M ; O U R M I S S I O N
A C A D E M I C P R O G R A M S
FA C U LT Y & STA F F PRO F I L E S
FA C U LT Y FO C U S: TH O M A S HA Z L E T
OU R ST U D E N TS & FE L L OWS
HO N O R S & A WA R D S
R E S E A R C H P R O G R A M S & G R A N T S
graduation 2001
(l to r):
Drs. Eric Johnson,
Sean Sullivan,
Todd Lee,
Mitch Higashi,
David Veenstra,
Nathorn
Chaiyakunapruk,
Tom Hazlet,
Holly Trautman, and
Jackie Gardner
Pha
rmac
euti
cal O
utc
omes
Res
earc
h an
d Po
licy
Pro
gram P E O P L E & P R O G R A M S
6
Our ProgramThe University of Washington (UW)
Department of Pharmacy created the
Pharmaceutical Outcomes Research and
Policy Program (PORPP) in 1995 with the
goal of advancing the health of the public
through improving decision-making in
regard to pharmaceutical therapy and
policy. Since that time, PORPP has helped
the UW become a nationally recognized
center for research in pharmaco-
epidemiology, pharmacoeconomics, and
pharmaceutical policy research. Recently,
PORPP has expanded its academic and
research programs and its mission to
include five related areas.
Our Mission■ Conduct research on the effects and uses of
pharmaceuticals in human populations.
■ Provide graduate and postgraduate training in
pharmaceutical outcomes research and policy.
■ Disseminate timely information regarding
pharmaceutical outcomes research and policies
to government, the pharmaceutical industry,
health care providers, and the general public.
■ Inform, through research and scholarship,
regional and national policies governing
pharmaceuticals and pharmaceutical services.
■ Be considered a resource for industry research,consultation, and training partnerships.
6
(l to r):
Dean Sid Nelson and
Dr. Phil Hansten
(Departmment of
Pharmacy)
at Graduation 2001
7
PhD in Pharmaceutical SciencesPharmaceutical outcomes research uses research
methods from a variety of disciplines, including
biostatistics, economics, and epidemiology to
evaluate clinical outcomes, morbidity, quality of
life, and cost-effectiveness. In the PhD program,
students are trained in economic evaluation,
pharmacoepidemiology, health services research,
outcomes assessment, and pharmaceutical policy
formulation and evaluation. The PhD in Pharma-
ceutical Sciences prepares students for career
opportunities in:■ Teaching and research at colleges and
universities.■ Safety and economic evaluation of products
in the pharmaceutical, biotechnology and
medical device industries.■ Policy analysis for professional associations,
health care insurance providers, and govern-
mental agencies.■ Management within hospitals, managed care
organizations, and programs concerned with
reimbursement for pharmaceuticals and other
medical technologies.
Concurrent Doctor of Pharmacy& Master’s DegreeThe combined Doctor of Pharmacy–Master’s
(PharmD–MS) Program in Pharmaceutical
Outcomes Research and Policy is targeted toward
outstanding students currently enrolled in the UW
School of Pharmacy’s Doctor of Pharmacy
program who have a proven interest in the field of
Outcomes Research and Policy. The concurrent
Academic Programs
The Department of Pharmacy offers two graduate degree options in its Pharmaceutical
Outcomes Research and Policy Program (PORPP): a PhD in Pharmaceutical Sciences,
and a combined Doctor of Pharmacy–Master of Science. The Program is enhanced by
several fellowship opportunities.
degree program allows these students to complete
both degrees within five years. Students complete
extensive graduate coursework and at least ten
credits of practicum and research training in a
managed care, government, industry, or other
appropriate setting. The program offers efficient
and specialized training in pharmaceutical
outcomes, through research experience and
didactic learning.
The demand for clinically trained students
with outcomes research capabilities is high in the
pharmaceutical, medical device, and managed
care industries, and will continue to grow. The
PharmD–MS program was created to meet this
demand.
FellowshipsPORPP is enhanced by a variety of fellowship
programs, including pre- and postdoctoral
fellowships, post-PharmD fellowships, and
managed care fellowships. Fellowships are
sponsored by foundations and the pharmaceutical
industry. During 2000–2002, the following
fellowships enabled students to reach their
academic goals:
■ American Foundation for Pharmaceutical
Education.■ AstraZeneca Managed Care Fellowship.■ Achievement Rewards for College Scientists.■ Blood Systems Foundation.■ Magnuson Scholar Award.■ Pharmaceutical Research and Manufacturers
of America Foundation.■ Roche Global Health Economics.
PhD, PharmD-MS, Fellowships
The demand for
clinically trained
students with
outcomes research
capabilities is high
in the pharma-
ceutical, medical
device, and
managed care
industries, and will
continue to grow
8
Science, and was elected to the Institute
of Medicine of the National Academy of
Science. In 1976, he was honored with the
Academy of Pharmaceutical Sciences
Research Achievement Award for Stimula-
tion of Research, and in 1980, he was
elected Honorary President of the Australia/
New Zealand Association for the Advance-
ment of Science, Pharmaceutical Sciences
Section. He is a consultant to FDA’s Center
for Drug Evaluation and Research, the
Veterans’ Administration Department of
Medicine and Surgery, and pharmaceutical
firms, including GlaxoSmithKline and
Roche. He is the author of nearly 200
articles and book chapters, has published
four books, and is the editor of the PORPP
Report and scientific editor of Pharmaco-
therapy. Dr. Gibaldi earned his BC from
Columbia College of Pharmacy and his
PhD from Columbia University.
Thomas K. Hazlet, PharmD, DrPHAssociate ProfessorDr. Hazlet completed a doctorate in
Pharmacy at the University of California
(UC), San Francisco and a residency in
hospital pharmacy at Yale-New Haven
Hospital. He earned a doctorate in Public
Health in the Health Policy and Adminis-
tration Program at UC Berkeley. His
background includes experience in
industrial microbiology with Baxter
Healthcare Corporation, parenteral
nutrition at UCLA Medical Center,
pharmacy practice in a community
hospital, as a Food and Drug Scientist
with the California Department of Health
Services’ Food and Drug Branch, and as
a member of the FDA’s Pacific Region
Biotechnology Team. His regulatory
activities include reviewing investigational
new drug applications and acting as a
technical liaison with field investigator staff,
clinical sponsors, industry representatives,
and legislators. Dr. Hazlet’s research is
directed toward assessing the consequences
of pharmaceuticals policy change and
teaching, research, serviceFaculty & Staff Profiles
FacultyDavid K. Blough, PhDClinical Associate ProfessorDr. Blough earned his PhD in Statistics
at Iowa State University. He has served
as collaborating statistician on numerous
research projects within the department,
including research on asthma, risk of
seizures associated with tramadol, adverse
drug reactions in the elderly, and the
evaluation of reference-based pricing
in British Columbia. Dr. Blough has
contributed to medical risk adjustment
methodology and to the development of
risk adjustment technology. His areas of
emphasis are generalized linear models,
the analysis of longitudinal data, and
mixed models.
Emily Beth Devine, PharmD, MBAResearch Assistant ProfessorAssociate Director, PORPPDr. Devine earned her doctorate in
Pharmacy from the University of the
Pacific and her MBA from the University
of San Francisco. She completed her
residency in clinical pharmacy practice
at the Veterans Affairs Medical Center
in Palo Alto, CA, and a postdoctoral
fellowship in pharmacoeconomics and
outcomes research with the UW. Her
research interests include patient safety,
pharmacoeconomic analyses of
hepatitis, and patients’ quality of life.
She serves on the executive committee
of the Section of Clinical Specialists of
the American Society of Health-System
Pharmacists, where she strives to
strengthen the role of the pharmacist in
research. She is also a member of the
International Society for Pharmaco-
economics and Outcomes Research.
Jacqueline S. Gardner, PhDAssociate ProfessorDr. Gardner earned a PhD in Epidemiology
from the UW School of Public Health and
Community Medicine in 1980. From 1980
to 1992, she worked for The Upjohn
Company, ultimately becoming Director of
Drug Epidemiology. Dr. Gardner’s research
focuses on the use and effects of drugs in
women and children, and on innovative
pharmacy practice. Her projects have
included examination of the use ofhormone replacement therapy by meno-
pausal women and the association of
maternal drug use during pregnancy with
craniosynostosis. She is responsible for
evaluating demonstration projects
designed to explore the outcomes of
extending prescriptive authority to
pharmacists to provide emergency contra-
ception. Dr. Gardner is a member of the
Washington State Pharmacy Association,
the Drug Information Association, the
International Society of Pharmaco-
epidemiology, the American Pharmaceu-
tical Association, and the Association of
Reproductive Health Professionals.
Milo Gibaldi, PhDDean Emeritus, School of PharmacyProfessor, Pharmaceutics and PharmacyFrom 1978 to 1995, Dr. Gibaldi was Dean of
the UW School of Pharmacy, where he also
was Associate Vice President for Health
Sciences and Chair of the Board of Deans.
He is a fellow of the Academy of Pharma-
ceutical Sciences and the American
Association for the Advancement of
9
includes an evaluation of reference pricing
in British Columbia’s Pharmacare pharma-
ceutical benefit and 3-tier co-payment
programs with Washington health insurers.
He is also interested in systems analysis of
medication errors in community pharmacy
practice and automation opportunities for
their amelioration.
Eric S. Johnson, PhDAssistant ProfessorDr. Johnson specializes in the design of
epidemiologic studies that evaluate drug
safety and describe the outcome of illness.
Most of his research investigates patients
with diabetes using population-based
registries and insurance databases. He
collaborates with investigators at the Center
for Health Research at Kaiser Permanente
Northwest. Dr. Johnson teaches a graduate
course on pharmacoepidemiology and
another on the principles of publishing
clinical evidence. He began his career in
epidemiology in 1991 at the US Centers
for Disease Control and Prevention,
evaluating blood product safety. He
earned an MPH in Health Services Research
in 1994 with a concentration in outcomes
research, and his PhD in Epidemiology
in 1999, both at the UW. Prior to joining
the Department of Pharmacy, Dr. Johnson
worked as an epidemiologist for Epide-
miology Resources, Inc. in Massachusetts.
He is a member of the International Society
of Pharmacoepidemiology and the
American Diabetes Association.
Donald L. Patrick, PhD, MSPHProfessorDr. Patrick is Senior Investigator, Center for
Disability Policy and Research, and Chair,
Social and Behavioral Sciences Program
Committee in the Department of Health
Services of the UW School of Public Health
and Community Medicine. He also directs
the Biobehavioral Cancer Prevention and
Control Training Program. In addition to
his appointment in PORPP, he holds
appointments in the Departments of
Epidemiology, Sociology, and Rehabilita-
tion Medicine. He publishes widely in the
areas of health status and quality of life
outcomes assessment, end-of-life care,
disability policy and research, health
promotion for older adults and persons
with disabilities, community intervention
and research, community priorities for
health care, resource allocation, and cost-
utility analyses. Dr. Patrick is a member of
the Institute of Medicine, the National
Academy of Sciences, and a Fellow of the
Academy for Health Services Research and
Health Policy.
Scott D. Ramsey, MD, PhDAssociate Professor and Director,Cancer Outcomes Research Program,Fred Hutchinson Cancer Research CenterDr. Ramsey earned his MD from the
University of Iowa and a PhD in Economics
from the Wharton School at the University
of Pennsylvania. He completed his
residency in internal medicine at the UW,
and was Chief Medical Resident for the
University Hospital. He also completed a
General Internal Medicine fellowship at the
Seattle VA Medical Center. He is Director
of the Cancer Outcomes Research Program
at the Fred Hutchinson Cancer Research
Center. He has served as the Health Analyst
for the US Senate Budget Committee. His
areas of interest include methods for
economic analyses in conjunction with
clinical trials, cost-effectiveness of genetic
screening for hereditary colon cancer, and
quality of life for cancer survivors and
colon cancer survivors. His current projects
include cost-effectiveness and quality of life
analyses of colon cancer screening and lung
reduction surgery for severe emphysema, an
economic evaluation of genetic screening
for colorectal cancer susceptibility, and a
project to compare the cost of therapies for
advanced lung cancer. Dr. Ramsey serves on
the editorial advisory boards of Expert
Review of Pharmacoeconomics & Outcomes
Research and the American Journal of
Managed Care.
Sean D. Sullivan, PhDProfessor and Director, PORPPDr. Sullivan earned his PhD in Health
Economics and Policy from UC Berkeley, an
MS in Pharmacy Administration from the
University of Texas, and a BS in Pharmacy
from Oregon State University. He com-
pleted a fellowship in Health Policy at the
UCSF Institute for Health Policy Studies,
and an NIH-funded fellowship in the
Economics of Aging at UC Berkeley. He
serves as principal investigator or co-
investigator on numerous health services
research and pharmaceutical costs and
outcomes assessment grants and contracts
and has published more than 100 papers,
book chapters, and books. He serves on the
editorial boards of PharmacoEconomics,
Pharmacotherapy, and Value in Health. His
research interests include the evaluation of
economic and health outcomes of interven-
tions for respiratory disorders, end-stage
renal disease, diabetes, cardiovascular
disease, osteoporosis, and mental health
disorders.
David L. Veenstra, PharmD, PhDAssistant ProfessorDirector, Postdoctoral PharmD ProgramsDr. Veenstra graduated from UC San
Francisco, where he completed concurrent
doctoral programs in Clinical Pharmacy
and Medicinal Chemistry. In medicinal
chemistry, his research centered on the
effect of amino acid mutations on protein
stability using computer modeling
techniques. Dr. Veenstra then conducted his
postdoctoral training in pharmaco-
economics with the UW from 1997–1999,
and spent one year working with Roche
Global Pharmacoeconomics in Palo Alto,
Scott Ramsey at spring picnic 2002
10
California. His methodologic expertise is in
cost-effectiveness modeling, including
decision analysis, Markov modeling, and
Monte Carlo simulation. His primary
research interests are the clinical, economic,
and policy implications of pharmaco-
genomic-based drug therapies. His projects
include studying the association between
drug metabolizing enzymes and adverse
drug reactions, estimating the cost-
effectiveness of pharmacogenomic
interventions, and evaluating the impact
of pharmacogenomics on the health care
system and pharmaceutical industry. He
holds a faculty appointment with the UW
Institute for Public Health Genetics. He has
experience in modeling chronic diseases
such as diabetes, hyperlipidemia, hyperten-
sion, and hepatitis B and C. As part of an
Academy of Managed Care Pharmacy
educational program, Dr. Veenstra has been
working with Pharmacy and Therapeutics
committees to assist them in evaluating
cost-effectiveness models submitted to
health care plans by manufacturers.
Dr. Veenstra is a member of the Society for
Medical Decision Making, the International
Society for Pharmacoeconomics and
Outcomes Research, and the American
Association for the Advancement of
Science. Dr. Veenstra is a recent recipient
of the Pharmaceutical Research and
Manufacturers Association Foundation
Career Development Award in Pharmaco-
economics.
Auxiliary FacultyD. S. (Pete) Fullerton, PhDAffiliate ProfessorDr. Fullerton is Vice-President of Pharmacy,
Regence Blue Shield. His expertise is in
achieving best practices in the managed
care environment. Specifically, he had led
the initiative entitled the Regence Format
for Formulary Submissions, a standardized
format for the submission of clinical and
economic information in support of
formulary consideration to Regence. This
effort has now evolved into the AMCP
(Academy of Managed Care Pharmacy)
Format for Formulary Submissions.
David Smith, RPh, MHA, PhDAffiliate Assistant ProfessorDr. Smith earned his pharmacy degree from
the University of Washington in 1990,
completed a residency in clinical pharmacy
and worked as a clinical pharmacist in
home care for several years. He received a
Master’s in Health Services Administration
in 1995, and was awarded a PhD in
Pharmaceutical Outcomes Research from
UW in 1998. He was the first doctoral
student to graduate from the PORPP
program. He then completed postdoctoral
work in economics at the University of
York, before returning to the Pacific
Northwest to conduct research with the
Kaiser Permanente Center for Health
Research in Portland, Oregon. His research
interests are in the economic evaluation of
health care technologies and pharmaco-
epidemiology.
Andy Stergachis, PhDAffiliate ProfessorDr. Stergachis is Senior Pharmacy Advisor
for drugstore.com and Principal and
Co-Founder of Formulary Resources, LLC.
He is an Affiliate Professor of Pharmacy
and Epidemiology at UW, and is affiliated
with The Hope Heart Institute in the area
of pharmaceutical research. Dr. Stergachis
served as Vice President and Chief
Pharmacist for drugstore.com, guiding
the organization from its prelaunch stage
through its present-day status as the
leading online drugstore. Formerly, he was
Chair of the UW Department of Pharmacy
and Founding Director of PORPP.
Previously, he worked for Group Health
Cooperative of Puget Sound in pharmacy
administration, and conducted health
research at the Center for Health Studies.
He earned his pharmacy degree from
Washington State University and his MS
and PhD in Pharmacy Administration from
the University of Minnesota. Dr. Stergachis
completed a postdoctoral fellowship in
health services research at the St. Louis Park
Medical Center, Minneapolis, Minnesota.
He was the 1990 Burroughs Wellcome
Scholar in Pharmacoepidemiology. The
American Association of Pharmaceutical
Research Scientists awarded him the 1994
Research Achievement Award in Economic,
Marketing, and Management Sciences. In
1999, American Druggist selected him as
one of the most influential pharmacists in
the United States. He has served as an
advisor to the National Institutes of Health,
the Agency for Healthcare Research and
Quality, and the Institute of Medicine.
He has published over 100 articles, book
chapters, and monographs, including work
in pharmacoepidemiology, managed care
pharmacy, internet pharmacy, and
pharmaceutical outcomes research. He
serves on the advisory boards of publica-
tions including the Hope Health Newsletter
of the Hope Heart Institute, P & T–
Pharmacy and Therapeutics, Pharmaco-
epidemiology and Drug Safety, Oncology
Economics, and the Journal of Managed
Care Pharmacy.
StaffCindy BushProgram Operations CoordinatorMs. Bush coordinates the Graduate and
Fellowship Programs. She also creates and
develops promotional materials, including
the PORPP web pages, and serves as the
contact person for current and prospective
faculty, fellows, students, and staff.
Penny EvansProgram CoordinatorMs. Evans coordinates the PORPP
programs including continuing education
conferences, seminars, and special events.
She also assists in the editing, preparation,
and dissemination of the quarterly
newsletter, The PORPP Report.
11
facult y focus
and the
UW extension certificate
program in biomedical
regulatory affairs
D r. (Tom) Hazlet’s background is notable for his work in the
regulatory affairs arena. He has used his experience as a Food
and Drug Scientist with the California Department of Health
Services, a member of the FDA’s Pacific Region Biotechnol-
ogy Team, and as an industrial manager in the pharma-
ceutical industry, to springboard to his current endeavor—
the UW Extension’s Certificate Program in Biomedical
Regulatory Affairs. Tom’s leadership, along with that of
colleagues in local industry, FDA, and the UW School of Law
and College of Engineering, has led to the creation of the
Certificate Program.
The eight-month evening certificate program’s course-
work provides a comprehensive overview of the knowledge
and skills necessary to be an effective regulatory affairs and
compliance specialist. Classes meet one evening per week in
Bellevue, Washington. In the first quarter, the course surveys
government oversight of drug, medical device and biotech-
nology-derived products; the laws and regulations that apply
to their development, testing and production; and the
responsibilities of a regulatory affairs specialist in the
regulatory setting. The second quarter emphasizes product
development and manufacturing concerns (such as quality
control, scale-up, good manufacturing practices and quality
systems), the FDA inspection process and FDA regulatory
actions. The third quarter focuses on post-marketing
requirements, reporting, and enforcement actions; emphasis
is on inspection—preparation, conduct of, and follow-up
actions. Post-marketing surveillance and studies, reimburse-
ment, and pharmacoeconomics issues are discussed.
Upon completion of the certification program, students
are eligible for employment opportunities where responsi-
bilities include overseeing the design, development, testing
and production of biologics, drugs and devices in the
industry setting.
Part of the certificate program’s richness derives from the
students, most of whom are employed by local manufactur-
ers. School of Pharmacy professional and graduate students
with an interest in manufacturing are encouraged to attend.
Significant interest in the certificate program has spurred
development of others. A certificate program in clinical trials
is nearing completion through UW Educational Outreach.
Future plans include the development of a graduate-level
certificate that includes courses from law, biomedical
engineering and business.
11
t h o m a s k . h a z l e t
12
Returning StudentsStudents in their second through fourth years ofthe PhD program:
Deborah Atherly, MPH
Debbie received a BS in Pharmacy and an MPH
from the UW. She joined the PhD program from
Parke-Davis Pharmaceuticals. Prior to that, she
worked at Regence Blue Shield, where she was
Director of Pharmacy and Formulary Manager.
She participated in the development of the
Regence (now AMCP) Format for Formulary
Submission Guidelines. In addition to a keen
interest in promoting the necessity of including
pharmacoeconomic data in the formulary
process, she is also interested in resource alloca-
tion in developing countries, HIV/AIDS, and
vaccines.
Denise Boudreau, MS, PhD Candidate
Denise earned both her BS in Pharmacy and her
MS in Pharmacy Administration at the University
of Rhode Island. A fourth-year PhD student,
Denise’s dissertation work brings together the
area of pharmacoepidemiology with issues in
breast cancer and women’s health.
Brian Custer, MPH, PhD Candidate
Brian received his BS in Biology from the Univer-
sity of Oregon and his MPH in Epidemiology at
the UW. His areas of interest include infectious
disease health outcomes, epidemiology, and
resource allocation. His PhD dissertation project
is focused on blood donation and blood product
safety. Other research interests include vaccine
development and the use of biotechnology in
health and medicine.
Thy Do, MS, MPH
Thy, a second-year PhD student, received his MS
from the State University of New York Stonybrook,
and his MPH from Yale University. Thy’s primary
interest is in the area of pharmacoepidemiology.
Our Students & Fellows new & returning
New StudentsIn the fall of 2001, PORPP welcomed threestudents to the graduate program inpharmaceutical outcomes:
Dana L. Hurley, PharmD
Dr. Hurley received both her BS in Pharmacy
and her PharmD from UW. She is employed as a
Clinical Outcomes Pharmacist at Premera Blue
Cross. Dana is pursuing the MS degree. Her areas
of research are cardiovascular and respiratory
diseases health outcomes.
Matthew Kerrigan, MSc
Matthew earned his BSc in Economics from the
University of Bradford in the United Kingdom
(UK), and his MS in Health Economics from the
University of York, UK. He joins us from Roche
Pharmaceuticals in Basel, Switzerland, where he
managed projects in pharmacoeconomics and
health technology assessment. Matthew is
enrolled in the PhD program.
Sarika S. Ogale, MS
Sarika received her BS in Pharmacy from Poona
College of Pharmacy in Pune, India, and her MS
in Pharmacy Administration from the University
of Louisiana at Monroe. She is enrolled in the
PhD program.
Our three new
students in the
graduate program in
pharmaceutical
outcomes (l to r):
Matthew Kerrigan,
Sarika Ogale,
Dana Hurley
13
Christopher Flowers, MS, MD
Dr. Flowers holds a BS degree in Human Biology,
a Master’s in Medical Information Sciences, and
an MD degree, all from Stanford University. He
is completing a second Master’s with PORPP.
He is enrolled in the UW/Robert Wood Johnson
Foundation Clinical Scholar’s program. His areas
of interest are the use of computer-based utility
assessment methods to examine drugs’ quality-of-
life benefits, and toxicity in phase I/II and phase
III oncology clinical trials.
Kristin Marciante, MPH, PhD Candidate
Kristin, a fourth-year PhD candidate, received
her BS in Biology and her MPH in Epidemiology
from Emory University. Her areas of interest
are clinical epidemiology and health program
evaluation. She has focused on contraception and
diabetes. Her dissertation project, “Modeling the
long-term, population-based outcomes of diabetic
retinopathy,” includes three studies: a validation
study of diagnosis and procedure codes used
to identify Kaiser Permanente type 2 diabetes
patients with retinopathy; an evaluation of Kaiser
Permanente type 2 diabetes patients’ adherence to
retinopathy screening and treatment guidelines;
and construction of a simulation model used to
estimate the incremental effectiveness of different
retinal screening strategies for preventing vision
loss in type 2 diabetics.
Nina Oestreicher, MS
Nina obtained her BS in Finance and Economics
from The Wharton School, University of Pennsyl-
vania. She received her MS in Epidemiology from
the UW. She is in her second year of the PhD
program. Her interest areas include analyses of
economic and health outcomes in cancer screening
and treatment, cardiovascular disease treatment,
genetic testing, and pharmacogenomics.
Karen Smith, BS
Karen received her BA in Biology from Sweet
Briar College in Virginia, and her BS in Pharmacy
from the University of Montana. In her second
year of the PhD program, Karen is interested in
costing and economic evaluations.
Scott Strassels, PharmD
Dr. Strassels received his PharmD
from the University of Arizona. After
completing a postdoctoral fellowship
in pharmacoeconomics with the UW
and GlaxoSmithKline, and practicing
pharmacy at the New England Medical
Center, Dr. Strassels returned to study in
the PhD program. His research interests
include epidemiology, economics, analgesia,
and chronic respiratory disease.
FellowsPORPP sponsors a postdoctoral fellowship inPharmacoeconomic and Outcomes Researchwith Roche Global Pharmacoeconomic Groupin Basel, Switzerland. This fellowship is designedfor Doctor of Pharmacy graduates who wish toenhance their skills in pharmacoeconomics andoutcomes research, and to prepare for employ-ment in the pharmaceutical or managed careindustries, or with policy-makers. Dr. DavidVeenstra is the Director of the FellowshipProgram.
Joanna C. Huang, PharmD
UW/Roche Pharmacoeconomic Fellow, 2000–2002
Dr. Huang received a BS degree in Chemistry and
Biology from Boston University in 1994, and her
PharmD degree from the UCSF in 2000. While
in school, she received Howard Hughes Medical
Institute funding for research in molecular
biology and genetics, and was an active member
of the California Pharmacists Association and the
California Society of Health-System Pharmacists.
Kavita K. Patel, PharmD, MBA
UW/Roche Pharmacoeconomic Fellow, 2001–2003
Dr. Patel received both her PharmD and MBA
from Drake University in 2001. While there, she
worked as a research assistant and conducted
drug utilization evaluations for the Pharmacy and
Therapeutics Committee. She is a member of the
International Society for Pharmacoeconomics
and Outcomes Research, the American Society of
Health-System Pharmacists, and the Illinois and
Iowa Pharmaceutical Associations.
he benefits of
PORPP are easy
to state:
the program
provides a
strong
grounding in
health
outcomes
research
coupled with
unlimited
opportunities
for student
collaboration
with the faculty.
—Brian Custer
t
13
14
Honors & Awards
FacultyDr. Jacqueline Gardner received the
Washington State Pharmacy Association
Special Achievement Award in 2001.
During 2001, Dr. Donald Patrick was
recognized with both the Robert Wood
Johnson Senior Health Policy Investigator
Award and the President’s Award, Interna-
tional Society for Quality of Life Research.
After completing a postdoctoral fellowship
at the University of York Centre for Health
Economics in 2000, Dr. David Smith was
appointed as an Honorary Visiting Research
Fellow at the University of York. This
appointment reflects ongoing collaboration
with researchers at York.
Dr. Andy Stergachis presented two guest
lectures: as the Melendy Lecturer at the
College of Pharmacy, University of Minne-
sota, and the Katterman Lecturer at the
School of Pharmacy, University of Washing-
ton, in 2000. In 2002, he also received the
APhA Foundation’s Pinnacle Award, which
recognizes individual career achievement
and contributions to health care quality
through improving the medication-use
process.
Dr. Sean Sullivan chaired the 6th Annual
(2001) International Meeting of the
International Society for Pharmaco-
economics and Outcomes Research.
Dr. David Veenstra received a Faculty
Development Award in Pharmaco-
economics, sponsored by the PhRMA
Foundation, and presented at the
6th Annual (2001) International
Meeting of the International Society for
Pharmacoeconomics and Outcomes
Research.
StudentsReceiving recognition at the 6th Annual
(2001) International Meeting of the
International Society for Pharmaco-
economics and Outcomes Research, were
students Debbie Atherly and Nathorn
Chaiyakunapruk, and faculty advisor
Sean Sullivan. Their poster was entitled
“Cost Impact of COX-2 Inhibitors in a
Managed Care Plan: Implications for
Formulary Decision-making.” Debbie was
interviewed for this research in the May
28, 2001 issue of the “Pink Sheet.”
Denise Boudreau received predoctoral
fellowship support from both the
American Council on Pharmaceutical
Education (2001 and 2002) and the
Pharmaceutical Research and Manufac-
turers of America Foundation Program
in Health Outcomes Research (2002).
Dr. Nathorn Chaiyakunapruk was the
recipient of the William A. Rutala Award
at the Association for Professionals in
Infection Control and Epidemiology, Inc.
(APIC) 2001 Annual Educational
Conference and International Meeting,
held in Seattle, on June 11, 2001. He
received this award for the abstract of his
dissertation research, “Which Antiseptic
Should We Use for Vascular Catheter Site
Care?” The APIC Abstract Selection
Committee nominates the top abstracts
in the category of disinfection, steriliza-
tion, and antisepsis. Selection of the
winning abstract is made by Dr. Rutala, a
world-renowned expert in the fields of
infection control, disinfection, steriliza-
tion, and medical waste.
Brian Custer received the Achievement
Reward for College Scientists (ARCS) for
1999–2002. The ARCS fellowship program
faculty & students
above:
Mitch Higashi in front of
his award-winning
poster at the 6th Annual
(2001) International
Meeting of the
International Society
for Pharmacoeconomics
and Outcomes Research.
opposite page:
Nina Oestreicher and
Kristin Marciante at
spring picnic 2002
15
Program is part of the Warren G.
Magnuson Institute for Biomedical
Research and Health Professional
Training, established in 1991 in honor of
the late Washington senator. The year
2001 marks the third year in a row that
Kristin has received the honor of this
scholarship. In 2000, she also received her
third and final year of the Achievement
Reward for College Scientists (ARCS).
Nina Oestreicher is the recipient of the
American Foundation for Pharmaceutical
Education predoctoral fellowship for
2002-2003. The primary goal of the AFPE
Fellowship program is to identify and
support those students who have the
potential to become leaders in the
pharmaceutical profession.
Holly Trautman is the recipient of the
2000 Facts and Comparison Award for
Excellence in Clinical Communication.
She completed her Master’s Degree with
support from the AstraZeneca Fellowship
in Managed Care Pharmacy (2001).
was begun following the launch of
Sputnik to provide three-year scholarships
to deserving students in the fields of
natural science, medicine, and engineer-
ing. To support his dissertation work,
Brian Custer has also received a Fellow-
ship in Blood Donor Epidemiology (2002)
from the Blood Systems Foundation.
Thy Do was awarded the Achievement
Reward for College Scientists (ARCS) in
2000, which is renewable for three years.
Mitch Higashi received the Best Poster
Presentation award at the 6th Annual
(2001) International Meeting of the
International Society for Pharmaco-
economics and Outcomes Research. His
work was entitled, “The Cost-Effectiveness
of Genetic Testing for Periodontal Disease:
A Payer’s Perspective.” In support of his
dissertation research, he received a grant
from the National Institute of Environ-
mental Health Sciences to study the effect
of CYP2C9 genotype on anticoagulation-
related outcomes during warfarin therapy;
and a grant from the UW Institute for
Public Health Genetics to study the cost-
effectiveness of implementing genetic
screening at anticoagulation clinics prior
to initiation of warfarin therapy.
In support of her master’s program,
Dr. Dana Hurley received support from
the AstraZeneca Fellowship in Managed
Care Pharmacy (2001–2002).
During the time he was a PhD candidate,
Dr. Todd Lee received a predoctoral
fellowship from the American Council on
Pharmaceutical Education to support his
dissertation work.
Kristin Marciante is the recipient of the
Magnuson Scholar Award. The Scholars
reat scientists and great
surfers share a common
trait. They don’t posi-
tion themselves where
the big wave is now,
they position themselves
where the next big wave
is going to be. PORPP
teaches students to read
the patterns in scientific
methods, to understand
the history that built up
behind the last big
waves, and to prepare
for the ride of your life
when you finally catch
the big one.
—Mitch Higashi
g
15
16
During
2000–2002,
PORPP
faculty
received over
$1.9 million
in funding—
$268,000 in
federal funds,
$1.5 million
in private
funds, and
$180,000 in
graduate
student
grants.
Research Programs & Grants
Program faculty have received funding from private and government entities to conduct research projects related to
pharmaceutical outcomes and policy. Major studies are underway on the health and cost outcomes of infectious
diseases; of chronic diseases such as asthma, hypertension, depression, schizophrenia, and end-stage renal disease; on
the safety of selected pharmaceutical and biotechnology products; and on pharmaceutical care practice issues.
for Child Health and Human
Development of National
Institutes of Health
Principal Investigator: GardnerCo-investigator: Marciante
Increasing Access to Emergency
Contraception in Rural Areas of
Washington State
Funding Source: Washington State
Dept. of Social and Health Services
Principal Investigator: Gardner
Outreach Services Center
(Provides consultative and profes-
sional services to the community)
Funding Source: Self-sustaining
Principal Investigator: Gardner
Health Costs and Outcomes with
Three-Tier Pharmacy Insurance
Benefit Plans
Funding Source: Aetna Quality
Care Research Fund
Principal Investigators: Hazlet and
BloughCo-investigators: Atherly, Fullerton,
Hurley, Sullivan, and Veenstra
Evaluation of an Intervention to
Improve Control of Type 2
Diabetes Mellitus, Medication
Adherence, and Medication Safety
in Adults
Funding Source: Aetna Quality
Care Research Fund
Principal Investigator: Odegard
Co-Investigators: Blough and
Johnson
Pre-Doctoral Fellowship in Blood
Donor Epidemiology
Funding Source: Blood Systems
Foundation
An investigation of the cost
effectiveness of nationally promoted
pediatric asthma guideline in three
managed care populations.
Funding Source: Agency for
Healthcare Research & Quality
Principal Investigator: SullivanCo-investigator: Blough
Benzodiazepine Use and Risk
of Disability in the Elderly
Funding Source: National
Institutes of Health
Principal Investigator: GrayCo-investigator: Blough
Cost and Outcome Evaluation
of Guideline Implementation for
the Treatment of Depression in
an Academic Medical Center
Managed Care Setting
Funding Source: Aetna Foundation
Principal Investigator: SullivanCo-investigator: Blough
Development and Validation of a
COPD Symptom-based Outcome
Measure
Funding Source: Genentech, Inc.
and Inspire Pharmaceuticals
Principal Investigator: SullivanCo-investigator: Blough
The Efficacy of Parental
Educational Materials in Reducing
Antibiotic Use
Funding Source: Aetna Foundation
Principal Investigator: Taylor
Co-investigator: Blough
Improving Contraceptive Practice
and Delivery through Community
Pharmacies
Funding Source: National Institute
Principal Investigator: JohnsonCo-investigator: Custer
Review of methods for measuring
drug therapy discontinuation
Funding Source: Pharmacia Corp.
Principal Investigator: Johnson
The Epidemiology and Cost of Drug
Therapy for Diabetes: A Population-
Based Cohort Study
Funding Source: GlaxoSmithKline
Principal Investigator: Johnson
Biobehavioral Cancer Prevention
and Control Training Program
Funding Source: National Cancer
Institute
Principal Investigator: Patrick
Development of a Clinical Tool for
Assessing Physical Activity Among
Older Adults
Funding Source: Centers for Disease
Control
Principal Investigator: Patrick
Managed Care and Physician
Satisfaction
Funding Source: Agency for
Healthcare Research and Quality
Co-investigator: Patrick
Quality of Life Among Youth with
Craniofacial Conditions: Phase II
Study
Funding Source: National Institute
for Dental and Craniofacial Research
Principal Investigator: Patrick
The Family Experience Pilot Study
Funding Source: Eli Lilly & Company
Principal Investigator: Patrick
Biobehavioral Cancer Prevention &
Control Training Program
‒
17
t
17
he PORPP
program has
enabled me to
not only have
an enriching
academic
experience,
but also has
given me the
opportunity
to collaborate
with a strong,
diverse group
of highly
talented and
experienced
individuals.
—Kavita Patel
The Cost effectiveness of Phot-
dynamic Therapy with
verteporftin
Funding Source: Novartis
Co-Investigator: Smith
Drug Safety Surveillance
Using United Health Group’s
Linked Databases, 2002-2004
Funding Source: Food and
Drug Administration
Principal Investigator: Shatin
Co-investigator: Stergachis
Costs, Outcomes and Cost-
Effectiveness of Dental
Services
Funding Source: Washington
Dental Services
Principal Investigator: Sullivan
Early Intervention with
Steroids in Asthma
Funding Source: AstraZeneca
Principal Investigator: Sullivan
Economic Model of Bipolar I
Disorder
Funding Source: GlaxoSmithKline
Principal Investigator: Sullivan
Graduate Research Fellowship
Funding Source: AstraZeneca LP
Principal Investigator: Sullivan
The Clinical and Economic
Implications of Genetic
Testing for Individualized
Drug Therapy: Warfarin and
the CYP2C9 Gene
Funding Source: UW Institute
for Public Health Genetics
Principal Investigator: Veenstra
The Role of Pharmaco-
genomics in the Genomics
Revolution
Funding Source: PhRMA
Foundation
Principal Investigator: Veenstra
UW/Roche Postdoctoral
Fellowship in Pharmaco-
economics Research
Funding Source: Roche Global
Pharmacoeconomic Research
Principal Investigator: Veenstra
development award)
Funding Source: National Cancer
Institute
Principal Investigator: Ramsey
The cost-effectiveness of lung
volume reduction surgery
Funding Source: National Heart,
Lung, and Blood Institute
Principal Investigator: Ramsey
Modelling the Long-Term, Popula-
tion-Based Outcomes of Diabetic
Retinopathy
Funding Source: Self-funded
Principal Investigators: Johnsonand Smith (with Marciante)
Analysis of 5-year secular trends in
antibiotic prescribing (1995–1999);
Examination of medication pre-
scribing patterns and impact on out-
comes for hospitalized heart failure
patient; Changes in the use of oral
antidiabetic agents associated with
medication co-payments.
Funding Source: Agency for Health-
care Research and Quality, HMO
Centers for Education and Research
in Therapeutics, (HMO CERTs).
Co-Principal Investigator: Smith
Describing the frequency of potential
errors of medication prescribing
black box warnings, drug lab moni-
toring, dosing in renal insufficiency,
drug use in the elderly, and drug
interactions; The use of alerts in the
electronic medical record (at Kaiser
Permanente Northwest) at time of
clinician medication order entry.
Co-Principal Investigator: SmithFunding Source: Agency for Health-
care Research and Quality, HMO
CERTs
Outcomes and Resource Use for
those with Kidney Dysfunction
Funding Source: Amgen
Principal Investigator: Smith
Modelling the Cost-effectiveness
of Oral Cancer Screening
Funding Source: The Health Tech-
nology Assessment Programme, UK
Co-Investigator: Smith
Funding Source: National Cancer
Institute R25 Training Grant
Principal Investigator: PatrickCo-Principal Investigator: Ramsey
Burden of illness and direct costs of
medical care of colon cancer
Funding Source: Aetna Foundation
Principal Investigator: Ramsey
CanCORS: Lung/Colon Cancer
Outcomes: Cancer Research Network
Funding Source: National Cancer Inst.
Principal Investigator: Weeks
Co-Investigator and Principal
Investigator for Special Project:
Ramsey
Correlation of Endoscopy Frequency
with Survival for Individuals
Diagnosed with Local and Regional
Colorectal Cancer
Funding Source: National Cancer
Institute
Principal Investigator: Ramsey
Evaluating the use of genetic
information. A model process
Funding Source: National Institute for
Human Genome Research
Principal investigator: BurkeCo-Investigator: Ramsey
Health Care Utilization and Direct
Medical Costs for Persons with Non-
Small Cell Lung Cancer
Funding Source: Bristol Myers Squibb
Principal Investigator: Ramsey
Interdisciplinary Model for Studying
Lung Cancer
Funding Source: FHCRC Institu-
tional Funds (Public Health Sciences
Division, Bid and Proposal Funding).
Principal Investigator: Ramsey
SEER Special Study #19: Feasibility
of Linking Health Systems Data to
Cancer Registry Data
Funding Source: National Cancer
Institute
Principal Investigator: Ramsey
The cost-effectiveness of genetic
screening for hereditary nonpoly-
posis colorectal cancer (Howard
Temin Award: 5-year career
18
PORPP
18
FA C U LT Y ACT I V I T I E S & SE RV I C E
CO R P O R AT E ADV I S O RY BOA R D
CO N F E R E N C E S & SY M P O S I A
FA C U LT Y FO C U S: SE A N SU L L I VA N
G R A N D R O U N D S S E M I N A R S E R I E SPha
rmac
euti
cal O
utc
omes
Res
earc
h a
nd
Polic
y P
rogr
am A C A D E M I C & C O M M U N I T Y I N T E R F A C E
19
Faculty Activities & Service
Dr. Jackie Gardner’s influence in the
arena of provision of emergency contra-
ception interventions by pharmacists has
led to a grant from the National Institute
for Child Health and Human Develop-
ment to study improved contraceptive
practice and delivery through community
pharmacies. It is a community-based
intervention study of the implementation
of a protocol to screen and supply
hormonal contraceptives through
community pharmacists. The study is
scheduled to be ongoing for four years.
Collaborators include Dr. Leslie Miller,
Director of Public Health Seattle-King
County Family Planning Clinics;
Stephanie Le, Fred Meyer Pharmacies;
and Don Downing, UW Department of
Pharmacy. PORPP faculty Dave Blough
and graduate student Kristin Marciante
will also participate.
Dr. Tom Hazlet’s success in studying
reference drug pricing in British Colum-
bia has led to receipt of a grant from the
Aetna Quality Care Research Fund to
study the health costs and outcomes with
three-tier pharmacy insurance benefit
plans in the Pacific Northwest of the US.
Drs. Scott Ramsey and Sean Sullivan
served on the national panel that
developed the “Guidelines for Prevention,
Screening and Treatment of Obstructive
Lung Disease.” The Guidelines are an
effort of the Global Obstructive Lung
Disease Initiative of the National Heart,
Lung, and Blood Institute, National
Institutes of Health, and the World
Health Organization.
Dr. David Smith was co-author on a
report that estimates the potential cost
and resource use implications of imple-
menting the mandate on reorganizing
cancer services from the influential
‘Calman-Hine’ report in the United
Kingdom. His report showed that a
critical factor in the cost of the reorgani-
zation would be the release of resources
from centers where care is currently
being provided. It was funded by the
Northern and Yorkshire Health Author-
ity, the largest Health Authority in the
UK, and provided a starting point for
policy negotiations on reorganization.
(Baughan S, Ferguson B, Hatfield A,
Smith DH, Wilkinson J. Implementing
Guidance Across Health Authorities: The
Case of Gynaecological Cancer. Nuffield
Portfolio Programme Report No. 11.
2000, University of Leeds)
Dr. Smith was also a co-investigator
on a report that is a part of the National
Beds Inquiry, a broad-based examination
of the need for additional inpatient ser-
vices in the UK National Health Service
and was commissioned by the Depart-
ment of Health. The report reviewed the
literature on avoidable use of inpatient
services and the cost-effectiveness of
alternatives to inpatient care. Ultimately,
recommendations from this report were
fed into the policy decision-making
process in the Department of Health.
(Goddard M, McDonagh M, Smith DH.
Avoidable use of Beds and Cost Effective-
ness of Care in Alternative Locations in
Shaping the Future NHS: Long Term
Planning for Hospitals and Related
Services. Consultation Document on the
Findings of the National Beds Inquiry—
Supporting Analysis. Published by the
NHS Executive. Crown Copyright 2000.)
Dr. Sean Sullivan evaluated the costs and
benefits of prescription drug discount
cards for the state of Washington. The
report was published pursuant to the
introduction of Washington State
Executive Order No. 00-04 to establish a
mechanism by which individuals age 55
and older, without current prescription
drug coverage, could obtain prescription
drugs from retail and mail order channels
of distribution at prices comparable to
those paid by the Washington State
Uniform Medical Plan (2001).
Along with experts from the Academy
of Managed Care Pharmacy, Sean Sullivan
led a national effort to standardize the
format of clinical and economic informa-
tion to support drug formulary decision-
making. The “AMCP Format for Formu-
lary Submissions” is being embraced by
managed care decision-makers and phar-
maceutical manufacturers nationwide.
Dr. David Veenstra’s work in the area of
pharmacogenomics is being well-received
in an environment where investigators,
clinicians and policy-makers are all
seeking information about how to apply
the theory of the human genome project
to clinical decision-making.
Policy Research ReportsThrough the years, PORPP faculty have been involved in the development of many
policy decisions, on both the state and national levels, where the work of PORPP
investigators informs decision-makers in a variety of areas. Below are highlighted
some of the recent contributions made by PORPP faculty. PORPP faculty are also
active on many advisory panels in their areas of specialty; and serve in leadership
positions with professional societies.
policy, panels, boards, societies
20
Jacqueline S. Gardner, PhD
Member, FDA Advisory Panel: Drug Safety and Risk Manage-
ment Subcommittee of the Pharmaceutical
Sciences Advisory Committee
Donald L. Patrick, PhD, MSPH
Consultant, Social Security Administration on Ticket to Work and
Work Incentives Improvement Act of 1999—Evaluation Advisor
(5 years)
Chair, NIH State-of-the-Art Conference on Treatment of Pain,
Depression and Fatigue
Consultant, European Union Development of Child Health Status
Measures
Scientific Advisor, Consumer Advisory Group, Model Spinal Cord
Injury System Grant, Northwest Regional SCI System
Scott D. Ramsey, MD, PhD
Advisory Board, Genentech, Inc.
Chair, FDA Medical Devices Dispute Resolution Panel
FDA Center for Devices and Radiologic Health
Andy Stergachis, PhD
Advisor, Verified Internet Pharmacy Practice Sites (VIPPS)
Program, National Association of Boards of Pharmacy
Board of Directors, Group Health Community Foundation
Health Systems Research Study Section of the Agency for
Healthcare Research and Quality
HEDIS Expert Pharmacy Panel, National Committee on Quality
Assurance
President-Elect and Board of Directors, Washington Poison Center
US-Swiss Joint Economic Commission. Planning Group for Panel
Discussion on “Bioterrorism: the Pharmaceutical Industry
Response” presented in conjunction with World Economic Forum,
New York, February, 2002
Sean D. Sullivan, PhD
Health Economics and Outcomes Research Advisory Board,
Aventis
Merck International Respiratory Advisory Board
Chair, Washington State Asthma Initiative, American Lung
Association of Washington
Advisory Panels & Corporate Boards
Professional SocietiesEmily Beth Devine, PharmD, MBA
Office of the Chair, Section of Clinical Specialists,
American Society of Health-System Pharmacists
(2000–2003)
D. S. Pete Fullerton, PhD
Incoming Member, Board of Directors, International
Society for Pharmacoeconomics and Outcomes
Research (2002–2004)
Sean Sullivan, PhD
Incoming Presidential Officer (2002–2004),
International Society for Pharmacoeconomics and
Outcomes Research
Dr. Jackie Gardner with
emergency contraception poster
at the 2002 Health Sciences
Open House
21
THE UW SCHOOL OF PHARMACY Corpo-
rate Advisory Board (CAB) first met in 1998 to
begin important discussions of areas of common
interest between faculty involved in pharmacy
education and corporate members of the
pharmaceutical industry. In late 2001, the CAB
reconvened to create a strategic partnership that
will propel PORPP into the future. On November
2, 2001, eleven colleagues from the pharmaceuti-
cal industry met with PORPP faculty for a day of
brainstorming ideas that will enhance our already
strong partnership, with the goal of strengthening
the PORPP program to meet the needs of
colleagues in the pharmaceutical industry. This
productive day concluded with a gathering atop
the Seattle World Trade Center, where Dean Sid
Nelson, Department Chair Dr. Danny Shen, and
the School of Pharmacy faculty welcomed CAB
members.
With the help of our CAB members, the
PORPP faculty were able to assess our current
levels of activity and plan our future goals in the
following areas:
■ Train researchers who understand the
perspective of, and are prepared to function at
a high level within the pharmaceutical
industry.■ Increase the number of PORPP graduates to
fill available positions in the pharmaceutical
industry.■ Develop the ability to respond to emerging
industry research needs, both in terms of
expertise of our graduates, and in terms of
faculty to conduct research (e.g., quality of life
and drug safety, respectively).■ Train those currently employed in the
industry setting, in the concepts of
pharmacoeconomics and outcomes research.
Corporate Advisory Board
y time as a
PORPP student has
been incredibly
fulfilling; I’ve made
lifelong friends and
received mentoring
from truly
outstanding faculty.
Thus, it is with a
mixture of sadness
and excitement that
I look forward to
graduating and
beginning a career
that will provide me
the opportunity to
apply the many
skills I’ve learned.
—Kristin Marciante
mCAB Members
Chair: Edward Bortnichak, MD, PhD
Sanofi-Synthelabo
Michael del Aguila, PhD
Washington Dental Services
D. S. (Pete) Fullerton, PhD, RPh
Regence Blue Shield
Louis Garrison Jr., PhD
Roche
Leonard Kirchdoerfer, PhD
Genentech
Grant Lawless, MD, RPh
Amgen
Sissi Pham, PharmD
GlaxoSmithKline
Phillip Sarocco, PhD
Aventis
Vipan Sood, RPh, MBA, MRPharmS
Pharmacia
Clifford Stocks, MBA
ICOS
Kent Summers, RPh, PhD
Lilly
21
strategic partnership
22
AMCP Format for Formulary SubmissionEducational SymposiaIn June 2001, in Vancouver, BC, PORPP faculty, along
with affiliated colleagues, conducted the first training
symposium for managed care practitioners on
implementing the AMCP Format for Formulary
Submission Guidelines. Presented in collaboration with
the Foundation for Managed Care Pharmacy, the
symposium was so well received that it became the
first of a repeated series in 2002. One and one-half
days in length, this symposium targets different
geographic areas of the United States to
train managed care decision-makers in the use of
the Format. Faculty included Drs. Pete Fullerton, Dell
Mather, Pete Penna, Scott Ramsey, Sean Sullivan,
David Veenstra, John Watkins, RPh, MPH, and from
AMCP—Steve Avey, RPh, and Richard Fry, RPh.
Spring ConferenceAn annual PORPP symposium, this year’s Spring
Conference featured an afternoon informing managed
care account executives and pharmaceutical industry
representatives about implementation of the AMCP
Format for Formulary Submission Guidelines by
managed care organizations. With over 100 attendees,
the symposium was held at the W Hotel in Seattle.
Faculty included Drs. Fullerton and Sullivan, Deborah
Atherly, RPh, MPH, and John Watkins, RPh, MPH.
Fall Clinical Conference
The annual PORPP Fall Clinical Conference was held
in October 2001, at the Elliott Grand Hyatt in Seattle.
Presented in partnership with the UW School of
Medicine, Division of Allergy and Infectious Diseases,
the UW School of Nursing, and the American Lung
Association, this conference reviewed “Therapeutic
Advances in Respiratory and Infectious Diseases.”
Attendees included practicing clinicians (medicine,
nursing, and pharmacy) in the Puget Sound area.
Presenting UW faculty included Drs. Henderson,
Redding, Shapiro, Hallstrand, Sullivan, Black and
Hansten.
Northwest Medical Director and Pharmacy BenefitManagers Quarterly Educational MeetingFall 2001 brought an opportunity for PORPP faculty
to share their expertise in a one-day program,
sponsored by the Northwest Medical Director and
Pharmacy Benefit Managers group, entitled “Critical
Evaluation of Clinical and Economic Data for
Formulary Decision-making.” Participating faculty
included Drs. Fullerton, Ramsey, Sullivan, Veenstra,
and John Watkins, RPh, MPH.
Managed Care Conference—Update on Treatmentand Management of Hepatitis CIn November 2001, PORPP sponsored a noontime
conference, presented by experts in the field of
hepatitis C. The “Update on Treatment & Management
of Hepatitis C” included speakers Willis Maddrey, MD,
University of Texas Southwestern Medical Center,
Dallas, and Robert Carithers, Jr., MD, University of
Washington. The audience included those in manage-
ment positions in regional health plans.
Attendees
at the
AMCP 2002
Formulary
Training
Symposium in
Orlando,
Florida
educational, clinicalConferences & Symposia
23
facult y focus
23
and the
AMCP Format for
Formulary Submission
Dr. Sean Sullivan, along with experts from the Academy of Managed Care Pharmacy
(AMCP), lead an effort to prepare a standardized format for the submission of
clinical and economic information to support drug formulary considerations
entitled, “The AMCP Format for Drug Formulary Submissions.” The document was
initially presented by Dr. Sullivan at the AMCP Educational Conference in San Diego
in October 2000. The Format is a tool intended for use by manufacturers when
submitting a dossier for drug formulary consideration by managed care organiza-
tions. Simultaneously, it is a tool for pharmacy directors to use in obtaining and
evaluating both clinical and pharmacoeonomic data provided by a pharmaceutical or
medical device company. The Format is a standardized template to draw evidence-
based conclusions about the clinical benefit and value of pharmaceuticals and
medical devices. The overarching purpose is to create more informed Pharmacy and
Therapeutics Committees nationwide—committees that are able to make increas-
ingly sound and rational formulary decisions.
Use of the Format has two goals. The first goal is to increase the timeliness,
comprehensiveness, and objectivity of information provided to the Pharmacy and
Therapeutics Committee. The second goal is to streamline the data acquisition and
review process for health plan pharmacists, as they undertake the evaluation process.
For example, with utilization of the Format, manufacturers are asked to provide
information about anticipated off-label uses of a product, thus enabling a more
informed decision for the health plan. Also unique to the Format is the request for an
economic model that demonstrates the anticipated populations in which the product
will provide the greatest value. Through collaboration between the pharmacists at
the health plans and benefit management organizations and the manufacturer, the
model can be tailored to the specific population under consideration, using data
from the health plan itself.
The precursor to the AMCP Format for Formulary Submissions was created by
pioneering work of Dr. Sullivan and three other PORPP members: Affiliate Professor
Dwight S. “Pete” Fullerton, PhD; former PORPP fellow Dell Mather, PharmD; and
PORPP graduate student, Deborah Atherly, RPh, MPH. Drs. Sullivan, Fullerton, and
Mather first created a set of formulary submission guidelines for use at Regence
BlueShield, a Seattle-based health plan covering 1.1 million lives. Ms. Atherly, as
Pharmacy Director and Formulary Manager, was an integral part of the development
process, providing important feedback that has led to their continual improvement
and eventual adoption by the prominent, national managed care organization for
pharmacists, AMCP.
The current focus of the developers is to increase awareness and utilization of
the Format nationwide. Since June of 2001, six educational symposia have been
conducted by the PORPP faculty, along with the AMCP Foundation. These symposia
have been provided in different locations throughout the United States. A separate
educational conference, targeted toward managed care industry liaisons, was recently
held in Seattle, and was well received.
From the global perspective, Australia, Canada, and other countries require
manufacturers to submit economic data and models when their products are
considered for inclusion in national formularies. The AMCP Format mirrors these
requirements, in a national environment wherein this information is not required,
but wherein interest in demonstrating value in the expensive marketplace of US
pharmaceuticals, is a welcome improvement.
The AMCP Format for Formulary Submissions can be viewed at:
http://www.amcp.org.
s e a n s u l l i v a n
24
Seminars 2000–2002Andrew Briggs, PhD
McMaster University, University of Oxford
Presenting Uncertainty in the Results of Cost-
Effectiveness Analysis to Aid Decision Making
for Disease Management, Specifically Diabetes
John Miall
Health Benefits Manager, City of Asheville
North Carolina
The Cost Benefit of Utilizing a Community
Pharmacist
Peter J. Neumann, DSc
Assistant Professor of Policy and Decisions
Sciences, Harvard School of Public Health
The FDA’s Regulation of Health Economic
Claims
Gerry Oster, PhD
Policy Analysis, Inc., Boston, Massachusetts
Designing and Analyzing Large, Simple Cost-
Effectiveness Trials
Grand Rounds Seminar Series
Cost and Outcomes SeriesThe Cost and Outcomes Grand Rounds
Seminar Series was established by PORPP in
1997 to provide a forum for leading experts
in cost and outcomes assessment to present
clinical and economic research concepts and
methods to UW researchers and trainees, as
well as members of the Seattle-area research,
health insurance, pharmaceutical,
biopharmaceutical, and medical device
industries. The Cost and Outcomes Grand
Rounds is jointly sponsored by PORPP, the
UW Center for Cost and Outcomes Research,
and the Outcomes Affinity Group at the Fred
Hutchinson Cancer Research Center.
Our most recent guest was Peter J.
Neumann, DSc, Assistant Professor of Policy
and Decision Sciences at the Harvard School
of Public Health. PORPP Director Sean
Sullivan welcomed Dr. Neumann on October
24, 2001. Dr. Neumann spoke to his audience
on “The FDA’s Regulation of Health Economic
Claims.” His talk stressed the importance and
evolutionary nature of this topic.
above: (l to r): Chris Flowers, Tom Hazlet, Sarika Ogale,
Karen Smith, and David Veenstra at Seminar
opposite page: Home of the UW School of Pharmacy
25
PORPP
25
NE W FA C U LT Y
FA C U LT Y FO C U S: DAV I D VE E N ST R A
NE W ALU M N I
VI S I T I N G SC H O LA R S
GR A D UAT E PRO G R A M RE V I E W
GR A D UAT E EM P L OY M E N T
SE L E CT E D PU B L I CAT I O N S
GR A N TS, GI F TS & AF F I L I AT I O N S
Pha
rmac
euti
cal O
utc
omes
Res
earc
h an
d Po
licy
Pro
gram O U R P R E S E N T ; O U R F U T U R E
26
New FacultyAssociate DirectorEmily Beth Devine, PharmD, MBA
In August 2001, PORPP welcomed Emily Beth
Devine as Associate Director and Research
Assistant Professor. Dr. Devine brings her
research, leadership, and clinical and business
skills to the PORPP program, and is looking
forward to advancing the program. She joined
PORPP upon completion of her UW/Roche
postdoctoral fellowship in pharmacoeconomics
and outcomes research. Dr. Devine earned her
doctorate in Pharmacy from the University of
the Pacific and her MBA from the University
of San Francisco. She completed her residency
in clinical pharmacy practice at the Veterans
Affairs Medical Center in Palo Alto, CA.
Her research interests include hepatitis,
electronic prescribing, and quality of life
evaluations. She began her career as a
prescribing pharmacist in the community
hospital setting, followed by several years on
the clinical faculty of the School of Pharmacy
at UC San Francisco, where she was respon-
sible for formulary management and guideline
development.
Dr. Devine is a fellow of the American
Society of Health-System Pharmacists and is
a board-certified pharmacotherapist specialist.
She is a member of the American Association
of Colleges of Pharmacy, the American
College of Clinical Pharmacy, the Academy of
Managed Care Pharmacy, the Drug Informa-
tion Association, and the International Society
for Pharmacoeconomics and Outcomes
Research. Dr. Devine was active for several
years with the California Society of Health-
System Pharmacists, serving both as board
member and presidential officer. During this
time, she supported legislation advancing
collaborative drug therapy management for
pharmacists. She serves on the executive
committee of the Section of Clinical Special-
ists of the American Society of Health-System
Pharmacists, where her efforts are in strength-
ening the role of the pharmacist in research.
Affiliate ProfessorMalcolm Maclure, ScD
Although Malcolm Maclure’s faculty
appointment to PORPP began very
recently (Spring 2002), he has a long
history with PORPP, having worked with
Dr. Stergachis, and more recently, with
Dr. Hazlet on the project evaluating
“Reference Pricing in British Columbia.”
Dr. Maclure received his BA in Biochem-
istry at Oxford and an MS and ScD in
Epidemiology from the Harvard School
of Public Health. He will collaborate
from his home position as Professor in
the School of Health Information Science
at the University of Victoria, British
Columbia. He has just been recognized as
a five-year Michael Smith Foundation for
Health Research Distinguished Scholar.
Dr. Maclure brings to PORPP his world-
renowned expertise in epidemiology and
extensive experience in working with
large-linked data sets. He will be
collaborating on projects and participat-
ing in classes and seminars. PORPP is
delighted to welcome him!
27
and
Pharmacogenomics
D avid Veenstra decided to pursue a career in pharmacoeconomics and outcomes
research toward the end of his graduate training at UC San Francisco. “I was
looking for a field that combined clinical evaluation and quantitative analysis,” he
recalls. “I was finishing my PhD in computational chemistry at the same time as
my PharmD, and pharmacoeconomics was the perfect fit.” He was offered a UW
postdoctoral fellowship, and headed to Seattle for formal training in the field. “I’ll
never forget—packing my stuff onto my motorcycle and riding up to Seattle. It was
like a whole new world opening up.”
Once at the UW, he quickly focused his efforts on cost-effectiveness modeling.
“I enjoyed the protein modeling and simulation work I had done during my PhD
training, and it was nice to transfer some of those skills to the clinical arena.” He
conducted research in technology assessment—in particular, evaluating novel
catheters designed to decrease the incidence of hospital-acquired infections. The
second year of his fellowship was spent with Roche Global Pharmacoeconomics in
Palo Alto, California. There, he learned more about the drug development process
and the role that pharmacoeconomics can play both in strategic decision making
in drug development and post-approval marketing. “I had a great opportunity to
be a member of several drug development teams,” an experience he says has been
invaluable. “It is difficult to understand the complexity of drug development
without participating in it directly. I think I had previously underestimated the
scientific challenges—and certainly the economic and political ones.”
After completing his postdoctoral training, Dr. Veenstra was offered a faculty
position with the UW, and decided to head back to Seattle. “That poor motorcycle.
I wore out yet another set of tires!” His objective was to pursue outcomes research
in the exciting new area termed ‘pharmacogenomics’—the use of genetic informa-
tion to guide individualized drug therapy. “Previously, I had studied the influence
of amino acid mutations on protein structure and stability. The thought of
evaluating the impact of genetic variants on clinical and economic outcomes was
just incredibly exciting.” Working in collaboration with his graduate student, Mitch
Higashi, and Dr. Kathryn Phillips of UC San Francisco, Dr. Veenstra developed a
cost-effectiveness framework for evaluating pharmacogenomic technologies. “We
published a paper directed toward the basic scientists in the field of pharmaco-
genomics, and the response has been tremendous. Clearly, there are a number of
important clinical, genetic, and economic issues that need to be sorted out quickly.
I think pharmacogenomic technologies will be coming to the market sooner than
most people realize.” He acknowledges that any paradigm shifts are decades away.
His most recent work was an evaluation of the risk of adverse outcomes in
patients taking warfarin (an anticoagulant) in relation to genetic variations in a
drug-metabolizing enzyme. CYP2C9 is a P450 enzyme that is responsible for the
primary metabolism of warfarin. About 30% of patients have at least one mutation
that prevents the proper metabolism of warfarin, theoretically putting these
patients at risk for bleeding events. Dr. Veenstra and his colleagues found that
patients with certain genetic variants were two times more likely to have a serious
or life-threatening bleeding event. “Is CYP2C9 genotyping cost effective? Well,
that’s exactly the next question we are attempting to answer. I think there will be a
lot of patients and clinicians out there wondering if they should be testing.”
Clearly, his work is relevant to many disciplines. Both as a PORPP faculty member,
and as a faculty member of the UW Institute for Public Health Genetics of the
School of Public Health and Community Medicine, Dr. Veenstra’s work will serve
to inform policies of the future.
27
facult y focusd a v i d v e e n s t r a
28
Nathorn Chaiyakunapruk, PharmD, PhD
Instructor, Department of Pharmacy Practice,
School of Pharmacy, Naresuan University
Dr. Chaiyakunapruk joined the PORPP
Graduate Program in 1997, with a PharmD
from the University of Wisconsin, and a BS in
Pharmacy from Chulalongkorn University,
Bangkok, Thailand. He received his PhD in
Pharmaceutical Outcomes at UW in Decem-
ber 2001, and has now returned to Thailand
where he is on the faculty at Naresuan
University. His dissertation was entitled,
“Meta-analysis and cost-effectiveness of
chlorhexidine gluconate and povidone iodine
In June 2001, PORPP graduated its first official “class” of masters and doctoral students. Among the graduates
were Nathorn Chaiyakunapruk, Mitchell K. Higashi, and Todd A. Lee, the first PhD students admitted into
our program in its inaugural year of 1997. The program’s first recipient of the combined PharmD-MS degree,
Holly Carlton Trautman, also graduated in 2001. All four have eagerly begun their new careers in academia or
industry. The PORPP faculty, students, and staff are extremely proud of our graduates.
New Alumni
use for the prevention of catheter-related
bloodstream infection.” His research interests
include technology assessment, systematic
reviews, and economic evaluation of phar-
maceuticals and services, particularly in the
areas of infectious disease, tropical medicine,
cardiovascular disease, and diabetes. He is
involved with a project, “Unmet need for drug
therapy in hospital visited patients,” funded
by Thai Health System Research Institute.
This project will use a large computerized
patient database to determine the magnitude
of inequity in receiving medications and
potential causes of problems.
PhD, PharmD-MS
29
Mitchell K. Higashi, MBA, PhD
Health Outcomes Scientist, GlaxoSmithKline
Dr. Higashi earned a PhD from PORPP
in 2001, an MBA from Eastern University,
Pennsylvania (1994), and a Bachelor’s degree
in Genetics, University of British Columbia,
Canada (1991). Dr. Higashi has held
positions in industry for Covance (Clinical
Research Associate) and Cardiome Pharma
(Director of Clinical Development). He
is now employed as a Health Outcomes
Scientist for GlaxoSmithKline.
Todd A. Lee, PharmD, PhD
Research Scientist, Hines VA Hospital
Research Assistant Professor,
Northwestern University
Adjunct Assistant Professor,
University of Illinois, Chicago
Dr. Lee earned a PhD from PORPP in 2001
and a PharmD from Drake University. He
is a senior investigator in the Midwest Center
for Health Services and Policy Research
(MCHSPR) housed at the Hines VA Hospital,
which is one of 13 VA Centers of Excellence.
He holds academic appointments in the
Center for Healthcare Studies in the North-
western University Feinberg School of
Medicine and the Department of Pharmacy
at the University of Illinois at Chicago. Prior
to joining MCHSPR, Dr. Lee was a managed
care fellow with Regence Blue Shield and
Premera Blue Cross in Washington state. He
also worked as a home care pharmacist. He is
working on several projects related to chronic
obstructive pulmonary disease (COPD) and
has published papers relating to the health
economics of asthma, COPD, and HIV.
Dr. Lee’s primary research focus is on patient
outcomes as they relate to the use of
pharmaceuticals, with a particular emphasis
on economic evaluation. Other research
interests include the use of economic
information in decision-making, evaluation
of quality of life, and cost-effectiveness
analyses in conjunction with clinical trials.
David Smith, RPh, MHA, PhD
Affiliate Assistant Professor
Research Scientist, Kaiser Center for
Health Research
Dr. David Smith was PORPP’s first graduate
from the PhD program. He earned his MHA
in 1995, and his PhD in Pharmaceutical
Outcomes in 1998, both from the University
of Washington. Following a two-year post-
doctoral fellowship at the University of York,
Dr. Smith is now developing his research
program at the Kaiser Center for Health
Research in Portland, Oregon. He is also an
affiliate faculty member of the PORPP
program.
Holly C. Trautman, PharmD, MS
Director of Pharmacy,
Community Health Plan of Washington
In 2001, Dr. Trautman became the first
recipient of the combined PharmD-MS
degree from PORPP. She earned a BA in
Medical Anthropology at Hampshire College
in Amherst, Massachusetts. She completed
a managed care fellowship while enrolled in
the PORPP program. She has worked as a
clinical pharmacist in diverse settings,
including home infusion, long-term care,
inpatient, outpatient, and managed care. As
Director of Pharmacy of Community Health
Plan of Washington, she is responsible for
formulary and clinical program develop-
ment, provider and member education and
outreach, academic programs, pharmacy
financials, and operations.
t
29
he training
I received at the
UW in PORPP
prepared me for all
facets of my day-
to-day work. The
didactic material
in the program
and the hands-on
research experi-
ence are invaluable
in handling issues
related to study
design or analysis
that I am con-
fronted with on a
daily basis.
—Todd Lee
Graduation 2001 (l to r):
Drs. Todd Lee, Mitch Higashi, Nathorn
Chaiyakunapruk, and Holly Trautman
30
In April 2001, the School of Pharmacy completed its 10-year Program
Review. The review committee consisted of reviewers both internal
and external to UW. The reviewers proclaimed the UW School of
Pharmacy to be a thriving center for excellence in research and
education. Due to its relative newness (1995), there was a specific
focus during the review on the PORPP program. The reviewers
commented on the sound foundation of the PORPP program, with
its strong leadership, excellent faculty, and notable student achieve-
ments. The committee indicated that PORPP has many of the
hallmarks of a thriving new educational enterprise. The reviewers
further commented on the ongoing collaborative work between
PORPP researchers and those at Fred Hutchinson Cancer Research
Center, the School of Public Health and Community Medicine, and
colleagues in the departments of pharmaceutics and medicinal
chemistry. Positive comments were also made about PORPP’s
curriculum.
In closing, the reviewers encouraged PORPP to augment
recruiting and expansion plans—a strong statement of encourage-
ment to those involved with the program!
Graduate Program Review
PORPP Welcomes Visiting Scholars
Andrew Street, PhD
On April 22, 2002, PORPP welcomed visiting scholar, Dr. Andrew
(Andy) Street to the UW campus. Dr. Street joins us from the
University of York, Center for Health Economics, where he is a Senior
Research Fellow. During his tenure at the UW campus, Dr. Street will
collaborate with PORPP faculty and students on research projects of
mutual interest, and participate in the weekly PORPP Seminar. His
tenure will extend to August 30, 2002. We look forward to working
with Dr. Street, and to further strengthening our bond with colleagues
at the University of York. Dr. Street was welcomed with a Departmen-
tal picnic, held in his honor.
Peter Smith, PhD
In 2000, Dr. Peter Smith joined us as a visiting scholar from the
University of York where he is Professor of Economics, Centre for
Health Economics. He has a joint appointment with the Department
of Economics and Related Studies, also at York. Dr. Smith is a mathe-
matics graduate of the University of Oxford. His research areas include
resource allocation, performance management, and productivity
analysis, both in the health care sector and in the broader public sector.
Visiting Scholars
Dr. Andy Street at spring picnic
31
Graduate Employment where they are now
MPH/MHA Managed Care ProgramsBrian Harris, MPH, 1988 Director of Pharmacy, Group Health Cooperative
Steve Hall, MPH, MHA, 1990 Account Manager Sanofi-Synthelabo
Linda Sturm, MPH, 1991 Associate Pharmacy Director, The Regence Group
Debbie Atherly, MPH, 1991 Student, UW/PORPP PhD Program
John Watkins, MPH, 1991 Formulary Director, Premera Blue Cross
David Hale, MHA, 1992 Intermountain Health Care, Salt Lake City, Utah
David Smith, RPh, MHA, 1995 Research Scientist, Kaiser Center for Health Research, Portland, Oregon
Joe Fazio, MPH, 1996 Northwest Pharmacy Services
Jennifer Hrachovec, MPH, 2001 Product Evaluator, Group Health Cooperative
Post-PharmD FellowshipsMary Helen Tran, PharmD, MBA, 1994 Senior Manager, Outcomes Research, Pfizer, Inc.
Libby Black, PharmD, 1995 Health Outcomes Manager, GlaxoSmithKline
Carmelina Battista, PharmD, 1996 Project Manager, MEDTAP International
Scott Strassels, PharmD, 1997 Student, UW/PORPP PhD Program
Dell Mather, PharmD, 1998 Prime Therapeutics
Welyn Chua Bui, PharmD, 1999 Senior Health Outcomes Research Consultant,
Lilly USA Health Outcomes Group
Essy Mozaffari, PharmD, 1995 Manager, Health Economics, Pharmacia
Reinee Sheffield, PharmD, 1997 Global Health Outcomes, Pharmacia
Darren Augenstein, PharmD, MBA, 1998 Pharmacist, Bartell Drugs
David Veenstra, PharmD, PhD, 1999 Assistant Professor, UW/PORPP Faculty
Doris Lew, PharmD, 2000 Kaiser Permanente, Oakland, CA
Beth Devine, PharmD, MBA, 2001 Research Assistant Professor, UW/PORPP Faculty
Post-PhD FellowshipsBJ Park, MD, PhD, 1993 Professor, Seoul University
Dan Malone, PhD, 1994 Associate Professor, Department of Pharmacy, Practice, and Science,
University of Arizona
Vlad Romano, MD, 1996 Faculty of Medicine, University of Romania
Olaf Klungel, PhD, 1999 Assistant Professor, University of Utrecht
Shelby D. Reed, PhD, 2000 Assistant Professor, Duke University, Clinical Health Policy Research
David Smith, RPh, MHA, PhD, 2000 Research, Scientist, Kaiser Center for Health Research, Portland, Oregon
Doctor of Philosophy, Pharmaceutical Outcomes
David Smith, RPh, MHA, PhD, 1998 Research Scientist, Kaiser Center for Health Research, Portland, Oregon
Nathorn Chaiyakunapruk, PharmD, PhD, 2001 Instructor, Department of Pharmacy Practice, Naresuan University, Thailand
Mitchell Higashi, MBA, PhD, 2001 Health Outcomes Scientist, GlaxoSmithKline
Todd Lee, PharmD, PhD, 2001 Research Scientist, Midwest Center for Health Services and Policy Research
Master’s Degree, Pharmaceutical Outcomes
Donna Marshall, PharmD, MS, 1999 Pharmacy Consultant, Uniform Medical Plan, Washington State
Sunshine Sommers, PharmD, MS, 1999 Pharmaceutical Outcomes Evaluator, Group Health Cooperative
Holly Carlton Trautman, PharmD, MS, 2001 Director of Pharmacy, Community Health Plan of Washington
32
Selected PublicationsFaculty2002Association between CYP2C9 genetic variantsand anticoagulation-related outcomes duringwarfarin therapy. Higashi MK, Veenstra DL,Kondo ML, Wittkowsky AK, SrinouanprachanhSL, Farin F, Rettie A. JAMA 2002;287:1690-1698.
Chlorhexidine compared with povidone-iodinesolution for vascular catheter-site care: A meta-analysis. Chaiyakunapruk N, Veenstra DL,Lipsky BA, Saint S. Ann Intern Med 2002;136(11):792-801.
Economic analyses and clinical practice guide-lines: why not a match made in heaven? RamseySD. J Gen Intern Med 2002 Mar;17(3):235-7.
Economic analysis of vinorelbine plus cisplatinversus paclitaxel plus carboplatin for advancednon-small-cell lung cancer. Ramsey SD, Moin-pour CM, Lovato LC, Crowley JJ, Grevstad P,Presant CA, Rivkin SE, Kelly K, Gandara DR.J Natl Cancer Inst 2002 Feb 20;94(4):291-7.
Increasing incidence of serious hypoglycemiain insulin users. Johnson ES, Koepsell TD,Reiber G, Stergachis A, Platt R. J Clin Epidemiol2002;55 (3):53-259.
Lifetime cancer-attributable cost of care forlong-term survivors of colorectal cancer.Ramsey SD, Berry K, Etzioni R.Am J Gastroenterol 2002 Feb;97(2):440-445.
Managed care and the US health care system:A social exchange perspective. Grembowski D,Cook K, Patrick DL, Roussel A. Social Scienceand Medicine 2002;54(8):67-1180.
Prevalence of serious eosinophilia and inci-dence of Churg-Strauss syndrome in a cohortof asthma patients. Loughlin JE, Cole JA,Rothman KJ, Johnson ES. Annals of Allergy,Asthma & Immunology 2002;88:319-325.
Productivity and medical costs of diabetesin a large employer population. Ramsey S,Summers KH, Leong SA, Birnbaum HG,Kemner JE, Greenberg P. Diabetes Care 2002Jan;25(1):23-9.
Socioeconomic issues related to antibiotic use.Reed SD, Laxminarayan R, Black D, SullivanSD. Ann Pharmacotherapy 2002;36:148-154.
The efficacy and tolerability of venlafaxinecompared with selective serotonin reuptakeinhibitors and other antidepressants: A meta-analysis. Smith DH, Dempster C, Glanville J,Freemantle N, Anderson I. Br J Psychiatry2002;180:396-404.
The practicality and validity of directly elicitedand SF-36 derived health state preferences inpatients with low back pain. Hollingsworth W,Deyo RA, Sullivan SD, Emerson S, Gray D,Jarvik JG. Health Econ 2002;11(1):71-85.
2001A comparison of diabetic foot ulcer patientsmanaged in VHA and non-VHA settings.Reiber GE, Smith DG, Carter J, Fotieo G,Deery HG, Sangeorzan JA, Lavery L, Pugh J,Bettine PR, Assal JP, del Aguila M, Diehr P,Patrick DL, Boyko EJ. J Rehabil Res Dev2001;May/June 38(3):309-317.
Age-related macular degeneration: cost of ill-ness issues. O’Neill C, Jamison J, McCulloch D,Smith D. Drugs and Aging 2001;18(4):233-41.
Abuse of futility. Curtis JR, Patrick DL,Caldwell ES, Collier AC. Arch of Intern Med2001;161(1):28-30.
AMCP guidance for submission of clinical andeconomic evaluation data to support formularylisting in US health plans and pharmacybenefits management organizations. Sullivan SD,Lyles A, Luce B, Gricar J. J Managed CarePharmacy 2001; 7(4):272-282.
An analysis of the cost and outcomes of emer-gency contraception prescribed by a pharma-cist in Washington State. Marciante KD,Gardner JS, Veenstra DL, Sullivan SD.Am J Pub Health 2001;91(9):1443-1445.
Comparison of the effectiveness of inhalerdevices in asthma and chronic obstructivepulmonary disease: A systematic review of theliterature. Brocklebank D, Ram F, Wright J,Cates C, Davies L, Douglas G, Muers M, SmithDH, White J. Health Technol Assess 2001;5(26).
Coronary artery bypass grafting in NativeAmericans: A higher risk for death than otherethnic groups? Nallamothu BK, Saint S, RamseySD, Fendrick M. J Gen Int Med 2001 Aug;16(8):554-559.
Cost and cost effectiveness of universal screen-ing for hearing loss in newborns. Kezirian EJ,White KR, Yueh B, Sullivan SD. Otolaryngol,Head Neck Surg 2001;124:359-67.
Cost-effectiveness of mircrosatellite instabilityscreening as a method for detecting hereditarynonpolyposis colorectal cancer. Ramsey SD,Clarke L, Etzioni R, Higashi M, Berry K, Urban N.Ann Intern Med 2001:135:577-588.
Design and analytic considerations in deter-mining the cost-effectiveness of early inter-vention in asthma from a multinational clinicaltrial. Sullivan SD, Liljas B, Buxton M, Lamm CJ,et al. Controlled Clinical Trials 2001; 22:420-437.
Design issues for conducting cost-effectivenessanalysis alongside randomized trials. RamseySD, McIntosh M, Sullivan SD. Annu Rev PublicHealth 2001;22:129-41.
Discounting for health effects in cost benefitand cost effectiveness analysis. Gravelle H,Smith DH. Health Econ 2001Oct;10(7):587-99.
faculty & students
33
Economic analysis of lung volume reductionsurgery as part of the National EmphysemaTreatment Trial. NETT Research Group.Ramsey SD, Sullivan SD, Kaplan RM, WoodDE, Chiang YP. Annals of Thoracic Surgery2001Mar;71(3):995-1002.
Economic evaluation of aquatic exercise forpersons with osteoarthritis. Patrick DL,Ramsey S, Spencer A, Kinne S, Belza B,Topolski T. Medical Care 2001; 39(5):413-424.
Economic evaluation of systemic treatments ofcytomegalovirus retinitis in patients with AIDS.Lee TA, Sullivan SD, Veenstra DL, Ramsey SD,Stefer PJK, Malinverni R, Pleil AM, Williamson T.Pharmacoeconomics 2001:19(5 Pt 2):535-550.
Emergency Contraception CollaborativePrescribing Experience in Washington State.Sommers SD, Chaiyakunapruk N, Gardner JS,Winkler J. J Am Pharm Assoc 2001;41:1-7.
Evaluating the quality of dying and death.Patrick DL, Engelberg RA, Curtis JR. J PainSymptom Manage 2001;Sep;22(3):717-26.
Factors associated with benzodiazepine use.Gray SL, Eggen AE, Blough DK. J Am GeriatrSoc 2001;49:S59.
Global strategy for the diagnosis, management,and prevention of chronic obstructivepulmonary disease. Pauwels RA, Buist AS,Calverly PM, Jenkins CR, Hurd SS, for theGOLD Scientific Committee. Am J Respir CritCare Med 2001;163:1256-1276.
Improving end-of-life experience and care inthe community: A conceptual framework.Byock I, Norris K, Curtis JR, Patrick DL. J PainSymptom Manage 2001;Sep;22(3):759-72.
Increasing access to emergency contraceptionthrough community pharmacies: Lessons fromWashington State. Gardner JS, Hutchings J,Fuller TS, Downing D. Family PlanningPerspectives 2001;33:172-175.
Inpatient costs, length of stay, and mortalityfor cerebrovascular events in communityhospitals. Reed SD, Blough DK, Meyer K,Jarvik JG. Neurology 2001;24:305-14.
International development of the Quality ofLife in Depression Scale (QLDS). McKenna SP,Doward LC, Kohlmann T, Mercier C, Niero M,Paes M, Patrick D, Ramirez N, Thorsen H,Whalley D. J Affect Disord 2001;Mar 63(1-3):189-99.
Lack of gender differences and large intra-subject variability in cytochrome P450 activitymeasured by phenotyping with dextromethor-phan. McCune JS, Lindley C, Decker JL,
Williamson KM, Meadowcroft AM, Graff D,Sawyer WT, Blough DK, Pieper JA. J ClinPharmacol 2001;41:723-31.
Management strategies for ribavirin-inducedhemolytic anemia in the treatment of hepatitisC: clinical and economics implications. DevineEB, Kowdley KV, Veenstra DL, Sullivan SD.Value in Health 2001;4(5):376-84.
Medication compliance in elderly patientsreceiving home health services following hospi-tal discharge. Gray, SL, Mahoney, J, Blough DK.Ann Pharmacother 2001;35:539-45.
Multicenter epidemiologic and health servicesresearch on therapeutics in the HMO ResearchNetwork–Center for Education and Researchon Therapeutics (CERT). Platt R, Davis R,Finkelstein J, Go AS, Gurwitz JH, Roblin D,Soumerai S, Ross-Degnan D, Andrade S,Goodman MJ, Marinson B, Raebel MA, SmithDH, Ukcickas-Yood M, Chan A. Pharmaco-epidemiol Drug Saf 2001 Aug-Sep;10(5):373-7.
Parameter solicitation for planning cost effec-tiveness studies with dichotomous outcomes.McIntosh M, Ramsey SD, Berry K, Urban N.Health Econ 2001;10:53-66.
Patients at high risk of death after lung-volume-reduction surgery. National Emphy-sema Treatment Trial Research Group.New Engl J Med 2001;345:1075-1083.
Patterns of self-rated health in older adultsbefore and after sentinel events. Diehr P,Williamson J, Patrick DL, Bild DE, Burke GL.J Am Geriatr Soc 2001;49(1):36-44.
Pharmacoeconomic impact of HMG-CoAreductase inhibitors in type 2 diabetes. Chai-yakunapruk N, Boudreau D, and Ramsey SD.J of Cardiovascular Risk 2001;8(3):127-132.
Probabilities of transition among health statesfor older adults. Diehr P, Patrick DL (2001).Qual Life Res 2001;10(5):431-42.
Quality of life and health-risk behaviors amongadolescents. Topolski TD, Patrick DL, EdwardsTC, Huebner CE, Connell FA, Mount KK.J Adolesc Health 2001;Dec 29(6):426-35.
Quality of life outcomes in the evaluation ofhead and neck cancer treatments. Schwartz S,Patrick D, Yueh Bevan. Arch Otolaryngol HeadNeck Surg 2001;June 127(6):673-78.
Randomized phase III trial of paclitaxel pluscarboplatin versus vinorelbine plus cisplatin inthe treatment of patients with advanced non-small-cell lung cancer: A Southwest OncologyGroup Trial. Kelly K, Crowley J, Bunn PA,Presane CA, Grevstad PK, Moinpour CM,
Ramsey SD, Wozniak AJ, Weiss GR, Moore DF,Israel VK, Livingston RB, Gandara DR.J Clin Oncol 2001;19(13):3210-3218.
Randomized trial of amplification strategies.Yueh B, Souza P, McDowell J, Sarubbi M, LoovisC, Hedrick S, Ramsey S, Deyo R. Arch Oto-laryngol Head Neck Surg 2001;127:1197-1204.
Recall bias in a prospective cohort study ofacute time-varying exposures: example fromthe herpetic eye disease study. Kip KE, Cohen F,Cole SR, Wilhelmus KR, Patrick DL, Blair RC,Beck RW. J Clin Epidemiol 2001;54(5):482-7.
Relative impact of patient and clinic factors oncompliance with primary care preventiveservices: An exploratory study. Ramsey SD,Cheadle AD, Neighbor WE, Gore E, Temple P,Staiger T, Goldberg HI. Medical Care 2001Sep;39(9):979-89.
Seattle 5-day worksite program to increasefruit and vegetable consumption. Beresford SA,Thompson B, Feng Z, Christianson A, McLerranD, Patrick DL. J Prev Med 2001:32(3):230-238.
The cost of liver transplantation for Medicarerecipients. Best JB, Veenstra DL, Geppert J,Lake J. Liver Transplantation 2001;7:858-862.
The costs of treating chronic obstructive pul-monary disease in the United States. StrasselsSA, Smith DH, Sullivan SD, Mahajan PS.Chest 2001;119:344-352.
The evolution and role of the online pharmacy.Stergachis A. P & T 2001;26:628-32.
The family conference as a focus to improvecommunication about end-of-life care in theintensive care unit: opportunities for improve-ment. Curtis JR, Patrick DL, Shannon SE,Treece PD, Engelberg RA, Rubenfeld GD. CritCare Med 2001Feb;29(2 Suppl):N26-33.
The health economics of asthma and allergicrhinitis: Part I. Assessing the economic impact.Weiss KB and Sullivan SD. J Allergy ClinImmunol 2001;107(1):3-8.
The health economics of asthma and allergicrhinitis: Part II. Sullivan SD and Weiss KB.J Allergy Clin Immunol 2001;107(2):203–210.
The impact of improved glycemic control onhealth care costs and utilization. Wagner EH,Sandhu N, Grothaus LC, Newton K, McCullochDK, Ramsey SD. JAMA 2001;285:182-89.
The impact of including future medical carecosts when estimating the costs attributableto a disease: A colorectal cancer case study.Etzioni R, Ramsey SD, Berry K, Brown M.Health Econ 2001 Apr;10(3):245-56.
34
The potential role of pharmacogenomics inpreventing adverse drug reactions: A syste-matic review. Phillips K, Veenstra DL, Oren E,Lee JK, Sadee WS. JAMA 2001;286:2270-2279.
The practice of discounting in economic eval-uation of health care interventions. Smith DH,Gravelle H. International J Health Technol Assess2001;17(2).
The role of hospital volume in coronary arterybypass grafting: is more always better? Nalla-mothu BK, Saint S, Ramsey SD, Hofer TP,Vijan S, Eagle KA. Journal of the AmericanCollege of Cardiology 2001;38(7):1923-30.
Transforming self-rated health and the SF-36scales to include death and improve interpret-ability. Diehr P, Patrick DL, Spertus J, Kiefe CI,McDonell M, Fihn SD. Medical Care 2001;39(7):670-680.
Treatment with tissue plasminogen activatorand inpatient mortality rates for patients withischemic stroke treated in community hospitals.Reed SD, Cramer SC, Blough DK, Meyer K,Jarvik JG. Stroke 2001;32:1832-40.
Use of alternative therapies by older adultswith osteoarthritis. Ramsey SD, Spencer AC,Topolski T, Belza B, Patrick DL. Arthritis andRheumatism 2001;June 45(3):222-227.
Washington State Alliance to Reduce PrescriptionDrug Spending: The “AWARDS” Program. Pre-pared for the Coalition for Affordable Prescrip-tions for Seniors. Sullivan SD, Kreling DH. 2001.
Weighted health status in the medicare popula-tion: Development of the Weighted HealthIndex for the Medicare Current BeneficiarySurvey (WHIMCBS). Doctor JN, Chan L,MacLehose RF, Patrick DL. Journal ofOutcome Measurement 2001;4(4):721-39.
2000A physician survey of the effect of drug sampleavailability on physicians’ behavior. Chew LD,O’Young TS, Hazlet TK, Bradley KA, MaynardC, Lessler DS. J Gen Intern Med 2000;15(7):478-483.
Antibiotics and clostridium difficile diarrhea inthe ambulatory setting. Levy DG, Stergachis A,McFarland LV, VanVorst K, Graham DJ,Johnson ES, Park BJ, Shatin DB, Clouse JC,Elmer GW. Clinical Therapeutics 2000;22:91-102.
Assessing the cost-effectiveness of pharmaco-genomics. Veenstra DL, Higashi MK, PhillipsKA. Pharmaceutical-Sciences 2000(Sept.14);2(3):Article 29.
Cost-benefit analysis of a clinical pharmacist’spresence on a post-liver transplant service.
Brethauer B, Devine EB, Jue M, Quan D, LouieC. Hospital Pharmacy 2000;35(11):1197-1202.
Direct medical costs of chronic obstructivepulmonary disease: chronic bronchitis andemphysema. Wilson L, Devine, EB, So K.Respir Med 2000;94;204-213.
Frequency and characteristics of cognitiveservices provided in response to a financialincentive. Christensen DB, Neil N, Fassett WE,Smith DH, Holmes G, Stergachis A.J Am Pharm Assoc 2000;40:609-17.
Incidence of adverse esophageal and gastricevents in alendronate users. Park BJ, Clouse J,Wysowski D, Shatin D, Stergachis A. J Phar-maco-epi and Drug Safety 2000;9:371-76.
Influence of a financial incentive on cognitiveservices: CARE Project Design/Implementa-tion. Christensen DB, Holmes G, Fassett WE,Neil N, Andrilla CH, Smith DH, Andrews A,Bell EJ, Hansen RW, Shafer R, Stergachis A.J Am Pharm Assoc 2000;40:629-39.
Measuring appropriate use of acute beds:A systematic review of methods and results.McDonagh MS, Smith DH, Goddard M.Health Policy, 2000 53. P 157-184.
Removal of drug samples from two teachinginstitutions [letter]. O’Young T, Hazlet TK.Am J Health Syst Pharm 2000;57(12):1179-1180.
Survey of Pharmacy Benefits. Prepared forWashington State Office of the InsuranceCommissioner. Hazlet TK, Bach M,Newcomer T. Spring 2000.
Tramadol and seizures: A surveillance studyin a managed care population. Gardner JS,Blough DK, Drinkard CR, Shatin D, AndersonGA, Graham D, Alderfer R. Pharmacotherapy2000; 20(12):1423-31.
Using generalized linear models to assessmedical care costs. Blough DK, Ramsey SD.Health Services and Outcomes Research
Methodology 2000;1:185-202.
Students2002Association between CYP2C9 genetic variantsand anticoagulation-related outcomes duringwarfarin therapy. Higashi MK, Veenstra DL,Kondo ML, Wittkowsky AK, SrinouanprachanhSL, Farin F, Rettie A. JAMA 2002;287:1690-1698.
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care:A meta-analysis. Chaiyakunapruk N, VeenstraDL, Lipsky BA, Saint S. Ann Intern Med 2002;136(11):792-801.
The association between breast carcinoma andmeningioma in women. Custer BS, Koepsell TD,Mueller BA. Cancer 2002 Mar15;94(6):1626-35.
2001Assessing the cost-effectiveness of pharmaco-genomics. Veenstra DL, Higashi MK, PhillipsKA. AAPS Pharmsci 2001;2(3)1-11.
An economic evaluation of systemic treatmentsfor cytomegalovirus retinitis in AIDS patients.Lee TA, Sullivan SD, Veenstra DL, Ramsey SD,Steger PJK, Malinverni R, Pleil AM, WilliamsonT. Pharmacoeconomics 2001;19(5 Pt 2): 535-550.
Cost-effectiveness of microsatellite instabilityscreening as a method for detecting hereditarynonpolyposis colorectal cancer. Ramsey SD,Clarke L, Etzioni R, Higashi M, Berry K, UrbanN. Ann Intern Med 2001 135 577-588.
Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. MarcianteKD, Gardner JS, Veenstra DL, Sullivan SD. AmJ Public Health 2001 91 1443-1445.
Performance of community pharmacy drug inter-action software. Hazlet TK, Lee TA, Hansten PD,Horn JR. J Am Pharm Assoc 2001;41(2):200-4.
Pharmacoeconomic impact of HMG-CoAreductase inhibitors in Type 2 Diabetes.Chaiyakunapruk N, Boudreau D, Ramsey SD.J Cardiovasc Risk 2001;Jun;8(3):127-32.
The costs of treating COPD in the UnitedStates. Strassels SA, Smith DH, Sullivan SD,Mahajan PS. Chest 2001 119 344-352.
The emergency contraception collaborativeprescribing experience in Washington State.Sommers SD, Chaiyakunapruk N, Gardner J,Winkler J. J Am Pharm Assoc 2001;41:60-6.
2000Breast density as a predictor of mammographicdetection: comparison of interval- and screen-detected cancers. Mandelson MT, OestreicherN, Porter PL, White E, Finder CA. J NationalCancer Institute 2000; 92:1081-7.
Comparison of the efficacy and cost effectivenessof preemptive therapy as directed by CMV anti-genemia and prophylaxis with ganciclovir in lungtransplant recipients. Kelly J, Hurley D, Raghu G.J Heart Lung Transplant 2000Apr;19(4):355-359.
Hip abductor weakness in distance runners withiliotibial band syndrome. Fredericson M,Cookingham CL, Chaudbari AM, Dowdell BC,Oestreicher N, Sahrmann SA. Clin J Sports Med2000;10:169-75.
The economic burden of COPD. Sullivan SD,Ramsey SD, Lee TA. Chest 2000;117: 5S-9S.
35
Grants & GiftsThe accomplishments of the Pharmaceutical
Outcomes Research & Policy Program in 2000-
2002 would not have been possible without
generous educational grants and gifts provided
by our sponsors. We wish to express our sincere
gratitude to:
Abbott Laboratories
AstraZeneca
Aventis Pharmaceuticals
Bayer Corporation
Bristol-Myers Squibb
Centacor, Inc.
Eli Lilly and Co.
Genentech, Inc.
GlaxoSmithKline
Janssen Pharmaceuticals
Merck & Company, Inc.
Pfizer Pharmaceuticals
Novartis
Pharmacia
Procter & Gamble
Regence Blue Shield
Sanofi-Synthelabo
Schering Plough
Sepracor, Inc.
The Everett Clinic
Wyeth-Ayerst Labs
AffiliationsAcademy of Managed Care Pharmacy
Fred Hutchinson Cancer Research Center
Group Health Cooperative of Puget Sound
Health Care Financing Administration
Kaiser Northwest Center for Health Research
NDC Health Information Service
Premera Blue Cross
Program for the Appropriate Use of
Technology in Health (PATH)
Regence Blue Shield and The Regence Group
Roche Global Pharmacoeconomic Research
State of Washington Department of Social
and Health Services
United HealthCare Corporation
University of British Columbia, Canada
University of Utrecht, The Netherlands
University of York, United Kingdom
UW Center for Cost & Outcomes Research
UW Medical Center and
affiliated teaching institutions
VA Puget Sound Health Care System
Washington Dental Service
Washington State Pharmacy Association
t he Master’s
training in
pharmaceutical
outcomes research
incorporated
many of the skills
that I use on a
daily basis in my
current position.
The hands-on
training that was
offered at local
institutions
offered invaluable
experiences,
which I reflect
upon
frequently.
—Holly C.
Trautman
33
36
Department of Pharmacy
University of Washington
Box 357630
Seattle, WA 98195-7630
Phone: 206-616-4587
FAX: 206-543-3835
Email: [email protected]
http://depts.washington.edu/porpp
PHAR MAC E UTI CAL OUTC O M E S
RE S EARC H AN D PO LI CY PRO G R AM
PORPP AdministrationDirector
Sean D. Sullivan, PhD
Associate Director
Emily Beth Devine, PharmD, MBA
Director of Post-PharmD Fellowship Programs
David L. Veenstra, PharmD, PhD
Program Operations Coordinator
Cynthia R. Bush
Program Coordinator
Penny L. Evans
Biennial Report TeamCynthia R. Bush
Emily Beth Devine
Penny L. Evans
Sean D. Sullivan
PhotosCindy Bush, Beth Devine, Penny Evans,
Tom Hazlet, Grace Lee, Mary Levin, UW Health SciencesCenter for Educational Resources, Kathy Sauber,
Cathy Schwartz, UW Photography
Design
Cathy Schwartz